FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Désiré Collen

Research Profile

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Goedele Wallays; Zsuzsanna Callaerts-Vegh; Peter Carmeliet; Désiré Collen; Rudi D'Hooge; Florea Lupu; Lieve Moons; Dieter Nuyens; Robert Silasi-Mansat; Joris Souffreau; An Van Nuffelen; Mieke Dewerchin
Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
Carmen Roncal; Ian Buysschaert; Norbert Gerdes; Maria Georgiadou; Olga Ovchinnikova; Christian Fischer; Jean Marie Stassen; Lieve Moons; Désiré Collen; Katrien De Bock; Göran K Hansson; Peter Carmeliet
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions.
Désiré Collen; H Roger Lijnen
The tissue-type plasminogen activator story.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Désiré Collen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Goedele Wallays; Zsuzsanna Callaerts-Vegh; Peter Carmeliet; Désiré Collen; Rudi D'Hooge; Florea Lupu; Lieve Moons; Dieter Nuyens; Robert Silasi-Mansat; Joris Souffreau; An Van Nuffelen; Mieke Dewerchin
Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
Arteriosclerosis, thrombosis, and vascular biology 2011;31(12):2881-8.
2010: Carmen Roncal; Ian Buysschaert; Norbert Gerdes; Maria Georgiadou; Olga Ovchinnikova; Christian Fischer; Jean Marie Stassen; Lieve Moons; Désiré Collen; Katrien De Bock; Göran K Hansson; Peter Carmeliet
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions.
Cardiovascular research 2010;86(1):29-36.
2009: Désiré Collen; H Roger Lijnen
The tissue-type plasminogen activator story.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(8):1151-5.
2008: Kristel Peeters; Jean Marie Stassen; Désiré Collen; Chris Van Geet; Kathleen Freson
Emerging treatments for thrombocytopenia: increasing platelet production.
Drug discovery today 2008;13(17-18):798-806.
2008: Glenn Marsboom; Peter Pokreisz; Olivier Gheysens; Pieter Vermeersch; Hilde Gillijns; Marijke Pellens; Xiaoshun Liu; Désiré Collen; Stefan Janssens
Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension.
Stem cells (Dayton, Ohio) 2008;26(4):1017-26.
2008: Anne Angelillo-Scherrer; Laurent Burnier; Diether Lambrechts; Richard J Fish; Marc Tjwa; Stephane Plaisance; Rocco Sugamele; Maria DeMol; Eduardo Martinez-Soria; Patrick H Maxwell; Greg Lemke; Stephen P Goff; Glenn K Matsushima; Henry Earp; Marc Chanson; Désiré Collen; Shozo Izui; Marc Schapira; Edward M Conway; Peter Carmeliet
Role of Gas6 in erythropoiesis and anemia in mice.
The Journal of clinical investigation 2008;118(2):583-96.
2007: Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean Marie Stassen; Mieke Dewerchin; Désiré Collen; Peter Carmeliet
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
Cell 2007;131(3):463-75.
2007: H Roger Lijnen; Berthe Van Hoef; D Kemp; Désiré Collen
Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity.
Biochimica et biophysica acta 2007;1770(9):1369-73.
2007: Pieter Vermeersch; Emmanuel Buys; Peter Pokreisz; Glenn Marsboom; Fumito Ichinose; Patrick Sips; Marijke Pellens; Hilde Gillijns; Marc Swinnen; Amanda R Graveline; Désiré Collen; Mieke Dewerchin; Peter Brouckaert; Kenneth D Bloch; Stefan Janssens
Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
Circulation 2007;116(8):936-43.
2007: Yasuhiro Suzuki; Nobuo Nagai; K Umemura; Désiré Collen; H Roger Lijnen
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
Journal of thrombosis and haemostasis : JTH 2007;5(8):1732-9.
2007: Peter Verhamme; Godelieve Goossens; Geert Maleux; Désiré Collen; Marguerite Stas
A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.
Journal of thrombosis and thrombolysis 2007;24(1):1-5.
2007: Femke Zwerts; Florea Lupu; Astrid De Vriese; Saskia Pollefeyt; Lieve Moons; Rachel A Altura; Yuying Jiang; Patrick H Maxwell; Peter Hill; Hideyasu Oh; Claus Rieker; Désiré Collen; Simon J Conway; Edward M Conway
Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure.
Blood 2007;109(11):4742-52.
2007: Jan Snoeys; joke lievens; Eddie Wisse; Frank Jacobs; Hans Duimel; Désiré Collen; Peter M Frederik; Bart De Geest
Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae.
Gene therapy 2007;14(7):604-12.
2007: Thierry VandenDriessche; Lieven Thorrez; A Acosta-Sanchez; I Petrus; Lin Wang; Ling Ma; L DE Waele; Y Iwasaki; Veerle Gillijns; James M Wilson; Désiré Collen; Marinee K L Chuah
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy.
Journal of thrombosis and haemostasis : JTH 2007;5(1):16-24.
2006: H Roger Lijnen; Marie-Christine Alessi; Liesbeth Frederix; Désiré Collen; Irène Juhan-Vague
Tiplaxtinin impairs nutritionally induced obesity in mice.
Thrombosis and haemostasis 2006;96(6):731-7.
2006: Gabor Voros; John D Sandy; Désiré Collen; H Roger Lijnen
Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development.
Biochimica et biophysica acta 2006;1760(12):1837-44.
2006: H Roger Lijnen; Valerie Christiaens; Ilse Scroyen; Gabor Voros; Marc Tjwa; Peter Carmeliet; Désiré Collen
Impaired adipose tissue development in mice with inactivation of placental growth factor function.
Diabetes 2006;55(10):2698-704.
2006: Lieven Thorrez; Herman H Vandenburgh; Nico Callewaert; Nico Mertens; Janet Shansky; Lin Wang; Jef Arnout; Désiré Collen; Marinee K L Chuah; Thierry VandenDriessche
Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(3):442-51.
2006: Marlies Van de Wouwer; Stephane Plaisance; Astrid De Vriese; E Waelkens; Désiré Collen; J Persson; M R Daha; Edward M Conway
The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.
Journal of thrombosis and haemostasis : JTH 2006;4(8):1813-24.
2006: Simon F De Meyer; Karen Vanhoorelbeke; Marinee K L Chuah; Inge Pareyn; Veerle Gillijns; Robert P Hebbel; Désiré Collen; Hans Deckmyn; Thierry VandenDriessche
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.
Blood 2006;107(12):4728-36.
2006: Diego Demeulemeester; Ilse Scroyen; Gabor Voros; Jan Snoeys; Bart De Geest; Désiré Collen; H Roger Lijnen
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development.
Thrombosis and haemostasis 2006;95(6):1019-24.
2006: Marc Jacquemin; Catherine M Radcliffe; Renaud Lavend'homme; Mark R Wormald; Luc VanderElst; G Wallays; J Dewaele; Désiré Collen; Jos Vermylen; Raymond A Dwek; Jean-Marie Saint-Remy; Pauline M Rudd; Mieke Dewerchin
Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.
Journal of thrombosis and haemostasis : JTH 2006;4(5):1047-55.
2006: Peter Pokreisz; Ingrid Fleming; Ladislau Kiss; Eduardo Barbosa-Sicard; Beate Fisslthaler; John R Falck; Bruce D Hammock; In-Hae Kim; Zsolt László Szelid; Pieter Vermeersch; Hilde Gillijns; Marijke Pellens; Friedrich Grimminger; Anton-Jan van Zonneveld; Désiré Collen; Rudi Busse; Stefan Janssens
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling.
Hypertension 2006;47(4):762-70.
2006: An Van Damme; Lieven Thorrez; Ling Ma; Herman H Vandenburgh; Jeroen Eyckmans; Francesco Dell'Accio; Cosimo De Bari; Frank P Luyten; David Lillicrap; Désiré Collen; Thierry VandenDriessche; Marinee K L Chuah
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells.
Stem cells (Dayton, Ohio) 2006;24(4):896-907.
2006: Patrick Rossignol; Aernout Luttun; Jose Luis Martin-Ventura; Florea Lupu; Peter Carmeliet; Désiré Collen; Eduardo Anglès-Cano; H Roger Lijnen
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.
Journal of thrombosis and haemostasis : JTH 2006;4(3):664-70.
2006: Fabrizio Semeraro; Gabor Voros; Désiré Collen; H Roger Lijnen
Impairment of adipose tissue development by hypoxia is not mediated by plasminogen activator inhibitor-1.
Thrombosis and haemostasis 2006;95(1):174-81.
2006: Jan Snoeys; Geertrui Mertens; joke lievens; Theo van Berkel; Désiré Collen; Erik A L Biessen; Bart De Geest
Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(1):98-107.
2005: Bart De Geest; Jan Snoeys; Sophie Van Linthout; joke lievens; Désiré Collen
Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone.
Human gene therapy 2005;16(12):1439-51.
2005: Gabor Voros; Erik Maquoi; Diego Demeulemeester; Natalie Clerx; Désiré Collen; H Roger Lijnen
Modulation of angiogenesis during adipose tissue development in murine models of obesity.
Endocrinology 2005;146(10):4545-54.
2005: Annelii Ny; Marta Koch; Martin Schneider; Elke Neven; Ricky T Tong; Sunit Maity; Christian Fischer; Stephane Plaisance; Diether Lambrechts; Christophe Héligon; Sven Terclavers; Malgorzata Ciesiolka; Roland Kälin; Wing Yan Man; Irena Senn; Sabine Wyns; Florea Lupu; André Brändli; Kris Vleminckx; Désiré Collen; Mieke Dewerchin; Edward M Conway; Lieve Moons; Rakesh K Jain; Peter Carmeliet
A genetic Xenopus laevis tadpole model to study lymphangiogenesis.
Nature medicine 2005;11(9):998-1004.
2005: Till Acker; Antonio Diez-juan; Julian Aragones; Marc Tjwa; Koen Brusselmans; Lieve Moons; Dai Fukumura; Maria Paz Moreno-Murciano; Jean-Marc Herbert; Angelika Burger; Johanna Riedel; Gerd Elvert; Ingo Flamme; Patrick H Maxwell; Désiré Collen; Mieke Dewerchin; Rakesh K Jain; Karl H Plate; Peter Carmeliet
Genetic evidence for a tumor suppressor role of HIF-2alpha.
Cancer cell 2005;8(2):131-41.
2005: Els Melis; Lieve Moons; Jef Arnout; Marc F Hoylaerts; Désiré Collen; Peter Carmeliet; Mieke Dewerchin
Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain.
Biochemical and biophysical research communications 2005;333(2):488-95.
2005: Nobuo Nagai; Yasuhiro Suzuki; Berthe Van Hoef; H Roger Lijnen; Désiré Collen
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Journal of thrombosis and haemostasis : JTH 2005;3(7):1379-84.
2005: H Roger Lijnen; Marie-Christine Alessi; Berthe Van Hoef; Désiré Collen; Irène Juhan-Vague
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.
Journal of thrombosis and haemostasis : JTH 2005;3(6):1174-9.
2005: Rohit Khurana; Lieve Moons; Shahida Shafi; Aernout Luttun; Désiré Collen; John F Martin; Peter Carmeliet; Ian Zachary
Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation.
Circulation 2005;111(21):2828-36.
2005: Désiré Collen; Marc F Hoylaerts
Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma.
Journal of the American College of Cardiology 2005;45(9):1472-3.
2005: Tom Rossenbacker; E Schollen; Cuno Kuipéri; T J L de Ravel; koenraad devriendt; G Matthijs; Désiré Collen; Hein Heidbüchel; Peter Carmeliet
Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy.
Journal of medical genetics 2005;42(5):e29.
2005: Erik Maquoi; Gabor Vörös; Peter Carmeliet; Désiré Collen; H Roger Lijnen
Role of Gas-6 in adipogenesis and nutritionally induced adipose tissue development in mice.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(5):1002-7.
2005: Désiré Collen; H Roger Lijnen
Thrombolytic agents.
Thrombosis and haemostasis 2005;93(4):627-30.
2005: Diego Demeulemeester; Désiré Collen; H Roger Lijnen
Effect of matrix metalloproteinase inhibition on adipose tissue development.
Biochemical and biophysical research communications 2005;329(1):105-10.
2005: Tom Rossenbacker; Kanigula Mubagwa; Roselie J Jongbloed; Johan Vereecke; koenraad devriendt; Marc Gewillig; Edward Carmeliet; Désiré Collen; Hein Heidbüchel; Peter Carmeliet
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.
Circulation 2005;111(8):961-8.
2005: Koen Brusselmans; Françoise Bono; Désiré Collen; Jean-Marc Herbert; Peter Carmeliet; Mieke Dewerchin
A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia.
The Journal of biological chemistry 2005;280(5):3493-9.
2005: Anne Angelillo-Scherrer; Laurent Burnier; Nathalie Flores; Pierre Savi; Maria DeMol; Paul Schaeffer; Jean-Marc Herbert; Greg Lemke; Stephen P Goff; Glenn K Matsushima; Henry Earp; Christian Vesin; Marc F Hoylaerts; Stephane Plaisance; Désiré Collen; Edward M Conway; Bernhard Wehrle-Haller; Peter Carmeliet
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.
The Journal of clinical investigation 2005;115(2):237-46.
2005: Stephane Heymans; Florea Lupu; Sven Terclavers; Bjorn Vanwetswinkel; Jean-Marc Herbert; Andrew Baker; Désiré Collen; Peter Carmeliet; Lieve Moons
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.
The American journal of pathology 2005;166(1):15-25.
2005: Xuri Li; Marc Tjwa; Lieve Moons; Pierre Fons; Agnès Noel; Annelii Ny; Jian Min Zhou; Johan Lennartsson; Hong Li; Aernout Luttun; Annica Pontén; Laetitia Devy; Ann Bouché; Hideyasu Oh; Ann Manderveld; Silvia Blacher; David Communi; Pierre Savi; Françoise Bono; Mieke Dewerchin; Jean-Michel Foidart; Monica Autiero; Jean-Marc Herbert; Désiré Collen; Carl-Henrik Heldin; Ulf Eriksson; Peter Carmeliet
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors.
The Journal of clinical investigation 2005;115(1):118-27.
2005: Erik Storkebaum; Diether Lambrechts; Mieke Dewerchin; Maria-Paz Moreno-Murciano; Saskia Appelmans; Hideyasu Oh; Philip Van Damme; Bart Rutten; Wing Yan Man; Maria De Mol; Sabine Wyns; David Manka; Kristel Vermeulen; Ludo Van Den Bosch; Nico Mertens; Christoph Schmitz; Wim Robberecht; Edward M Conway; Désiré Collen; Lieve Moons; Peter Carmeliet
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.
Nature neuroscience 2005;8(1):85-92.
2004: Marinee K L Chuah; Désiré Collen; Thierry VandenDriessche
Preclinical and clinical gene therapy for haemophilia.
Haemophilia : the official journal of the World Federation of Hemophilia 2004;10 Suppl 4():119-25.
2004: Yasuhiro Suzuki; Feng Chen; Yicheng Ni; Guy Marchal; Désiré Collen; Nobuo Nagai
Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.
Stroke; a journal of cerebral circulation 2004;35(10):2402-6.
2004: joke lievens; Jan Snoeys; Katrien Vekemans; Sophie Van Linthout; Ronald de Zanger; Désiré Collen; Eddie Wisse; Bart De Geest
The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer.
Gene therapy 2004;11(20):1523-31.
2004: Yasuhiro Suzuki; Nobuo Nagai; Désiré Collen
Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.
Journal of thrombosis and haemostasis : JTH 2004;2(9):1617-21.
2004: Marlies Van de Wouwer; Désiré Collen; Edward M Conway
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(8):1374-83.
2004: Stefan Janssens; Peter Pokreisz; Luc Schoonjans; Marijke Pellens; Pieter Vermeersch; Marc Tjwa; Peter Jans; Marielle Scherrer-Crosbie; Michael H Picard; Zsolt László Szelid; Hilde Gillijns; Frans Van de Werf; Désiré Collen; Kenneth D Bloch
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.
Circulation research 2004;94(9):1256-62.
2004: Marinee K L Chuah; Désiré Collen; Thierry VandenDriessche
Clinical gene transfer studies for hemophilia A.
Seminars in thrombosis and hemostasis 2004;30(2):249-56.
2004: An Van Damme; Marinee K L Chuah; Désiré Collen; Thierry VandenDriessche
Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
Seminars in thrombosis and hemostasis 2004;30(2):185-95.
2004: Lieven Thorrez; Thierry VandenDriessche; Désiré Collen; Marinee K L Chuah
Preclinical gene therapy studies for hemophilia using adenoviral vectors.
Seminars in thrombosis and hemostasis 2004;30(2):173-83.
2004: Désiré Collen; H Roger Lijnen
Tissue-type plasminogen activator: a historical perspective and personal account.
Journal of thrombosis and haemostasis : JTH 2004;2(4):541-6.
2004: Aernout Luttun; Esther Lutgens; Ann Manderveld; Katleen Maris; Désiré Collen; Peter Carmeliet; Lieve Moons
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.
Circulation 2004;109(11):1408-14.
2004: Gabor Voros; Erik Maquoi; Désiré Collen; H Roger Lijnen
Influence of membrane-bound tumor necrosis factor (TNF)-alpha on obesity and glucose metabolism.
Journal of thrombosis and haemostasis : JTH 2004;2(3):507-13.
2004: Tino Hochepied; Luc Schoonjans; Jeroen Staelens; Veerle Kreemers; Sophie Danloy; Leen Puimège; Désiré Collen; Frans van Roy; Claude Libert
Breaking the species barrier: derivation of germline-competent embryonic stem cells from Mus spretus x C57BL/6 hybrids.
Stem cells (Dayton, Ohio) 2004;22(4):441-7.
2004: Mieke Dewerchin; L Van der Elst; I Singh; Sabrina Grailly; Jean-Marie Saint-Remy; Désiré Collen; Marc Jacquemin
Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice.
Journal of thrombosis and haemostasis : JTH 2004;2(1):77-84.
2004: H Roger Lijnen; Berthe Van Hoef; K Umans; Désiré Collen
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1).
Journal of thrombosis and haemostasis : JTH 2004;2(1):16-22.
2003: Marinee K L Chuah; Désiré Collen; Thierry VandenDriessche
Biosafety of adenoviral vectors.
Current gene therapy 2003;3(6):527-43.
2003: Thierry VandenDriessche; Désiré Collen; Marinee K L Chuah
Biosafety of onco-retroviral vectors.
Current gene therapy 2003;3(6):501-15.
2003: Veerle Compernolle; Koen Brusselmans; Diego Franco; Antoon Moorman; Mieke Dewerchin; Désiré Collen; Peter Carmeliet
Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha.
Cardiovascular research 2003;60(3):569-79.
2003: Mieke Dewerchin; Jean-Pascal Hérault; Goedele Wallays; Maurice Petitou; Paul Schaeffer; Laurence Millet; Jeffrey I Weitz; Lieve Moons; Désiré Collen; Peter Carmeliet; Jean-Marc Herbert
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin.
Circulation research 2003;93(11):1120-6.
2003: Anneleen Janssen; Pierre Gressens; Markus Grabenbauer; Eveline Baumgart; Arno Schad; Ilse Vanhorebeek; Annelies Brouwers; Peter E Declercq; Dariush Fahimi; Philippe Evrard; Luc Schoonjans; Désiré Collen; Peter Carmeliet; Guy P Mannaerts; Paul P Van Veldhoven; Myriam Baes
Neuronal migration depends on intact peroxisomal function in brain and in extraneuronal tissues.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2003;23(30):9732-41.
2003: Randall W Moreadith; Désiré Collen
Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction.
Advanced drug delivery reviews 2003;55(10):1337-45.
2003: Edward M Conway; Femke Zwerts; Veerle Van Eygen; Astrid DeVriese; Nobuo Nagai; Wei Luo; Désiré Collen
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation.
The American journal of pathology 2003;163(3):935-46.
2003: Thierry VandenDriessche; Désiré Collen; Marinee K L Chuah
Gene therapy for the hemophilias.
Journal of thrombosis and haemostasis : JTH 2003;1(7):1550-8.
2003: Monica Autiero; Johannes Waltenberger; David Communi; Andrea Kranz; Lieve Moons; Diether Lambrechts; Jens Kroll; Stephane Plaisance; Maria De Mol; Françoise Bono; Stefanie Kliche; Guido Fellbrich; Kurt Ballmer-Hofer; Domenico Maglione; Ulrike Mayr-Beyrle; Mieke Dewerchin; Saskia Dombrowski; Danica Stanimirovic; Paul van Hummelen; Christoph Dehio; Daniel J Hicklin; Graziella Persico; Jean-Marc Herbert; David Communi; Masabumi Shibuya; Désiré Collen; Edward M Conway; Peter Carmeliet
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
Nature medicine 2003;9(7):936-43.
2003: Paul W Armstrong; Désiré Collen; Elliott M Antman
Fibrinolysis for acute myocardial infarction: the future is here and now.
Circulation 2003;107(20):2533-7.
2003: Koen Brusselmans; Veerle Compernolle; Marc Tjwa; Michael S Wiesener; Patrick H Maxwell; Désiré Collen; Peter Carmeliet
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.
The Journal of clinical investigation 2003;111(10):1519-27.
2003: Erik Maquoi; Diego Demeulemeester; Gabor Vörös; Désiré Collen; H Roger Lijnen
Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation.
Thrombosis and haemostasis 2003;89(4):696-704.
2003: Bart De Geest; Sophie A Van Linthout; Désiré Collen
Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells.
Blood 2003;101(7):2551-6.
2003: Marinee K L Chuah; Gudrun Schiedner; Lieven Thorrez; Brian Brown; Marion Johnston; Veerle Gillijns; Sabine Hertel; Nico van Rooijen; David Lillicrap; Désiré Collen; Thierry VandenDriessche; Stefan Kochanek
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Blood 2003;101(5):1734-43.
2003: Wim Janssens; Marinee K L Chuah; Luigi Naldini; Antonia Follenzi; Désiré Collen; Jean-Marie Saint-Remy; Thierry VandenDriessche
Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent.
Human gene therapy 2003;14(3):263-76.
2003: Nobuo Nagai; E Demarsin; Berthe Van Hoef; S Wouters; D Cingolani; Yves Laroche; Désiré Collen
Recombinant human microplasmin: production and potential therapeutic properties.
Journal of thrombosis and haemostasis : JTH 2003;1(2):307-13.
2003: H Roger Lijnen; Diego Demeulemeester; Berthe Van Hoef; Désiré Collen; Erik Maquoi
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice.
Thrombosis and haemostasis 2003;89(2):249-55.
2003: Gabor Voros; Erik Maquoi; Désiré Collen; H Roger Lijnen
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories.
Biochimica et biophysica acta 2003;1625(1):36-42.
2003: An Van Damme; Marinee K L Chuah; Francesco Dell'Accio; Cosimo De Bari; Frank P Luyten; Désiré Collen; Thierry VandenDriessche
Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
Haemophilia : the official journal of the World Federation of Hemophilia 2003;9(1):94-103.
2003: Luc Schoonjans; Veerle Kreemers; Sophie Danloy; Randall W Moreadith; Yves Laroche; Désiré Collen
Improved generation of germline-competent embryonic stem cell lines from inbred mouse strains.
Stem cells (Dayton, Ohio) 2003;21(1):90-7.
2003: H Roger Lijnen; Erik Maquoi; Pierre Morange; Gabor Voros; Berthe Van Hoef; Francis Kopp; Désiré Collen; Irène Juhan-Vague; Marie-Christine Alessi
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(1):78-84.
2002: Michael Praus; Désiré Collen; Robert D Gerard
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
International journal of cancer. Journal international du cancer 2002;102(6):584-91.
2002: Zsolt László Szelid; Peter Sinnaeve; Pieter Vermeersch; Hilde Gillijns; Marijke Pellens; Veerle Laurysens; Natascha Van Pelt; Willem Flameng; Paul Sergeant; Paul Herijgers; Peter Pokreisz; Anton-Jan van Zonneveld; Erik Verbeken; Désiré Collen; Stefan Janssens
Preexisting antiadenoviral immunity and regional myocardial gene transfer: modulation by nitric oxide.
Human gene therapy 2002;13(18):2185-95.
2002: Sophie Van Linthout; M Lusky; Désiré Collen; Bart De Geest
Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Gene therapy 2002;9(22):1520-8.
2002: Edward M Conway; Marlies Van de Wouwer; Saskia Pollefeyt; Kerstin Jurk; Hugo Van Aken; Astrid De Vriese; Jeffrey I Weitz; Hartmut Weiler; Peter W Hellings; Paul Schaeffer; Jean-Marc Herbert; Désiré Collen; Gregor Theilmeier
The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways.
The Journal of experimental medicine 2002;196(5):565-77.
2002: Gregor Theilmeier; Peter Verhamme; Steven Dymarkowski; Heike Beck; Hilde Bernar; Marleen Lox; Stefan Janssens; Marie-Christine Herregods; Erik Verbeken; Désiré Collen; Karl H Plate; Willem Flameng; Paul Holvoet
Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density.
Circulation 2002;106(9):1140-6.
2002: H Roger Lijnen; Erik Maquoi; Diego Demeulemeester; Berthe Van Hoef; Désiré Collen
Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity.
Thrombosis and haemostasis 2002;88(2):345-53.
2002: Edward M Conway; Saskia Pollefeyt; Marta Steiner-Mosonyi; Wei Luo; Astrid Devriese; Florea Lupu; Françoise Bono; Nathalie Leducq; Frédérique Dol; Paul Schaeffer; Désiré Collen; Jean-Marc Herbert
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways.
Gastroenterology 2002;123(2):619-31.
2002: Thierry VandenDriessche; Lieven Thorrez; Luigi Naldini; Antonia Follenzi; Lieve Moons; Zwi Berneman; Désiré Collen; Marinee K L Chuah
Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo.
Blood 2002;100(3):813-22.
2002: Gregor Theilmeier; Rozenn Quarck; Peter Verhamme; Marie-Luce Bochaton-Piallat; Marleen Lox; Hilde Bernar; Stefan Janssens; Mark Kockx; Giulio Gabbiani; Désiré Collen; Paul Holvoet
Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty.
Cardiovascular research 2002;55(2):385-95.
2002: Aernout Luttun; Marc Tjwa; Lieve Moons; Yan Wu; Anne Angelillo-Scherrer; Fang Liao; Janice A Nagy; Andrea Hooper; Josef Priller; Bert De Klerck; Veerle Compernolle; Evis Daci; Peter Bohlen; Mieke Dewerchin; Jean-Marc Herbert; Roy Fava; Patrick Matthys; Geert Carmeliet; Désiré Collen; Harold F Dvorak; Daniel J Hicklin; Peter Carmeliet
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
Nature medicine 2002;8(8):831-40.
2002: Aernout Luttun; Koen Brusselmans; Hideharu Fukao; Marc Tjwa; Shigeru Ueshima; Jean-Marc Herbert; Osamu Matsuo; Désiré Collen; Peter Carmeliet; Lieve Moons
Loss of placental growth factor protects mice against vascular permeability in pathological conditions.
Biochemical and biophysical research communications 2002;295(2):428-34.
2002: Veerle Compernolle; Koen Brusselmans; Till Acker; Peter Hoet; Marc Tjwa; Heike Beck; Stephane Plaisance; Yuval Dor; Eli Keshet; Florea Lupu; Benoit Nemery; Mieke Dewerchin; Paul P Van Veldhoven; Karl H Plate; Lieve Moons; Désiré Collen; Peter Carmeliet
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice.
Nature medicine 2002;8(7):702-10.
2002: Peter Sinnaeve; Jean-Daniel Chiche; Hilde Gillijns; Natascha Van Pelt; Douglas Wirthlin; Frans Van de Werf; Désiré Collen; Kenneth D Bloch; Stefan Janssens
Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis.
Circulation 2002;105(24):2911-6.
2002: Gregor Theilmeier; Carine Michiels; Erik Spaepen; Ingrid Vreys; Désiré Collen; Jos Vermylen; Marc F Hoylaerts
Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia.
Blood 2002;99(12):4486-93.
2002: Virginie Mattot; Lieve Moons; Florea Lupu; Daniel Chernavvsky; R Ariel Gómez; Désiré Collen; Peter Carmeliet
Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice.
Journal of the American Society of Nephrology : JASN 2002;13(6):1548-60.
2002: J Silence; Désiré Collen; H Roger Lijnen
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene.
Circulation research 2002;90(8):897-903.
2002: An Van Damme; Thierry Vanden Driessche; Désiré Collen; Marinee K L Chuah
Bone marrow stromal cells as targets for gene therapy.
Current gene therapy 2002;2(2):195-209.
2002: Sophie Van Linthout; Désiré Collen; Bart De Geest
Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.
Human gene therapy 2002;13(7):829-40.
2002: Inderjit Singh; Alberto Smith; Beatrijs Vanzieleghem; Désiré Collen; Kevin Burnand; Jean-Marie Saint-Remy; Marc Jacquemin
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model.
Blood 2002;99(9):3235-40.
2002: Petra A M Warmerdam; Stephane Plaisance; Kristel Vanderlick; Petra Vandervoort; Kathleen Brepoels; Désiré Collen; Marc De Maeyer
Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling.
Thrombosis and haemostasis 2002;87(4):666-73.
2002: Erik Maquoi; Carine Munaut; Alain Colige; Désiré Collen; H Roger Lijnen
Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity.
Diabetes 2002;51(4):1093-101.
2002: H Roger Lijnen; Hoef B Van; Liesbeth Frederix; M C Rio; Désiré Collen
Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity.
Thrombosis and haemostasis 2002;87(3):530-5.
2002: Aernout Luttun; Florea Lupu; Erik Storkebaum; Marc F Hoylaerts; Lieve Moons; James Crawley; Françoise Bono; A Robin Poole; Peter Tipping; Jean-Marc Herbert; Désiré Collen; Peter Carmeliet
Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(3):499-505.
2002: H Roger Lijnen; Erik Maquoi; L B Hansen; Berthe Van Hoef; Liesbeth Frederix; Désiré Collen
Matrix metalloproteinase inhibition impairs adipose tissue development in mice.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(3):374-9.
2002: Myriam Baes; Mieke Dewerchin; Anneleen Janssen; Désiré Collen; Peter Carmeliet
Generation of Pex5-loxP mice allowing the conditional elimination of peroxisomes.
Genesis (New York, N.Y. : 2000) 2002;32(2):177-8.
2002: Ingeborg Stalmans; Yin-Shan Ng; Richard M Rohan; Marcus Fruttiger; Ann Bouché; Ali Yuce; Hajime Fujisawa; Bart Hermans; Moshe Shani; Sandra Jansen; Daniel J Hicklin; David J Anderson; Tom Gardiner; Hans-Peter Hammes; Lieve Moons; Mieke Dewerchin; Désiré Collen; Peter Carmeliet; Patricia A D'Amore
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms.
The Journal of clinical investigation 2002;109(3):327-36.
2002: Christa Maes; Peter Carmeliet; Karen Moermans; Ingrid Stockmans; Nico Smets; Désiré Collen; Roger Bouillon; Geert Carmeliet
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
Mechanisms of development 2002;111(1-2):61-73.
2002: Thierry VandenDriessche; Luigi Naldini; Désiré Collen; Marinee K L Chuah
Oncoretroviral and lentiviral vector-mediated gene therapy.
Methods in enzymology 2002;346():573-89.
2002: Petra A M Warmerdam; Kristel Vanderlick; Petra Vandervoort; Heidi De Smedt; Stephane Plaisance; Marc De Maeyer; Désiré Collen
Staphylokinase-specific cell-mediated immunity in humans.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(1):155-61.
2001: Sophie van Cromphaut; Mieke Dewerchin; Joost G J Hoenderop; Ingrid Stockmans; Erik Van Herck; S Kato; René J M Bindels; Désiré Collen; Peter Carmeliet; Roger Bouillon; Geert Carmeliet
Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(23):13324-9.
2001: Mark Ver Heyen; Stephane Heymans; Gudrun Antoons; T Reed; Muthu Periasamy; Bonaventure L Awede; Jean Lebacq; Peter Vangheluwe; Mieke Dewerchin; Désiré Collen; Karin R Sipido; Peter Carmeliet; Frank Wuytack
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.
Circulation research 2001;89(9):838-46.
2001: Koen Brusselmans; Françoise Bono; P Maxwell; Yuval Dor; Mieke Dewerchin; Désiré Collen; Jean-Marc Herbert; Peter Carmeliet
Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia.
The Journal of biological chemistry 2001;276(42):39192-6.
2001: Pieter Vermeersch; Z Nong; E Stabile; Olivier Varenne; Hilde Gillijns; Marijke Pellens; Natascha Van Pelt; Marc F Hoylaerts; I De Scheerder; Désiré Collen; Stefan Janssens
L-arginine administration reduces neointima formation after stent injury in rats by a nitric oxide-mediated mechanism.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(10):1604-9.
2001: Thierry VandenDriessche; Désiré Collen; Marinee K L Chuah
Viral vector-mediated gene therapy for hemophilia.
Current gene therapy 2001;1(3):301-15.
2001: Désiré Collen
Revival of plasmin as a therapeutic agent?
Thrombosis and haemostasis 2001;86(3):731-2.
2001: J Silence; Florea Lupu; Désiré Collen; H Roger Lijnen
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(9):1440-5.
2001: Dieter Nuyens; Milan Stengl; S Dugarmaa; Tom Rossenbacker; Veerle Compernolle; Yoram Rudy; Jos F M Smits; Willem Flameng; colleen clancy; Lieve Moons; Marc A Vos; Mieke Dewerchin; Klaus Benndorf; Désiré Collen; Edward Carmeliet; Peter Carmeliet
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome.
Nature medicine 2001;7(9):1021-7.
2001: Els Melis; Lieve Moons; Maria De Mol; Jean-Marc Herbert; Nigel Mackman; Désiré Collen; Peter Carmeliet; Mieke Dewerchin
Targeted deletion of the cytosolic domain of tissue factor in mice does not affect development.
Biochemical and biophysical research communications 2001;286(3):580-6.
2001: Mieke Dewerchin; Désiré Collen; H Roger Lijnen
Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
Thrombosis and haemostasis 2001;86(2):640-6.
2001: Paul W Armstrong; Désiré Collen
Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2.
Circulation 2001;103(24):2987-92.
2001: Paul W Armstrong; Désiré Collen
Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1.
Circulation 2001;103(23):2862-6.
2001: H Roger Lijnen; Berthe Van Hoef; Désiré Collen
Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1.
Biochimica et biophysica acta 2001;1547(2):206-13.
2001: Rozenn Quarck; Bart De Geest; DOMINIQuE STENGEL; Ann Mertens; Marleen Lox; Gregor Theilmeier; Carine Michiels; M Raes; Hidde Bult; Désiré Collen; P Van Veldhoven; Ewa Ninio; Paul Holvoet
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.
Circulation 2001;103(20):2495-500.
2001: Nobuo Nagai; Maria De Mol; Berthe Van Hoef; M Verstreken; Désiré Collen
Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Blood 2001;97(10):3086-92.
2001: L Moons; I Vanlinthout; Ivo Roelants; Randall W Moreadith; Désiré Collen; H J Rapold
Toxicology studies with recombinant staphylokinase and with SY 161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant.
Toxicologic pathology 2001;29(3):285-91.
2001: Paul Holvoet; Ann Mertens; Peter Verhamme; Kris Bogaerts; G Beyens; Raymond Verhaeghe; Désiré Collen; Erik Muls; F Van de Werf
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(5):844-8.
2001: Peter Carmeliet; Lieve Moons; Aernout Luttun; V Vincenti; Veerle Compernolle; Maria De Mol; Y Wu; Françoise Bono; Laetitia Devy; Heike Beck; Dimitri Scholz; Till Acker; T DiPalma; Mieke Dewerchin; Agnès Noel; Ingeborg Stalmans; A Barra; Silvia Blacher; Thierry VandenDriessche; A Ponten; Ulf Eriksson; Karl H Plate; Jean-Michel Foidart; Wolfgang Schaper; D S Charnock-Jones; Daniel J Hicklin; Jean-Marc Herbert; Désiré Collen; M Graziella Persico
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
Nature medicine 2001;7(5):575-83.
2001: M Levi; Lieve Moons; Ann Bouché; S D Shapiro; Désiré Collen; Peter Carmeliet
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Circulation 2001;103(15):2014-20.
2001: F Ugwu; Griet Lemmens; Désiré Collen; H Roger Lijnen
Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity.
Thrombosis research 2001;102(1):61-9.
2001: H Roger Lijnen; F Bloemmen; Annie J Vereecken; Désiré Collen
Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples.
Thrombosis research 2001;102(1):53-9.
2001: Khalid Bajou; Véronique Masson; Robert D Gerard; P M Schmitt; V Albert; Michael Praus; Leif R Lund; Thomas L Frandsen; Nils Brunner; K Dano; Norbert E Fusenig; UH Weidle; G Carmeliet; D Loskutoff; Désiré Collen; Peter Carmeliet; Jean-Michel Foidart; Agnès Noël
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
The Journal of cell biology 2001;152(4):777-84.
2001: Edward M Conway; Désiré Collen; Peter Carmeliet
Molecular mechanisms of blood vessel growth.
Cardiovascular research 2001;49(3):507-21.
2001: MC Beckers; Jan Gabriels; Silvère M van der Maarel; Astrid De Vriese; R R Frants; Désiré Collen; A Belayew
Active genes in junk DNA? Characterization of DUX genes embedded within 3.3 kb repeated elements.
Gene 2001;264(1):51-7.
2001: Anne Angelillo-Scherrer; P de Frutos; C Aparicio; Els Melis; Pierre Savi; Florea Lupu; Jef Arnout; Mieke Dewerchin; Marc F Hoylaerts; J Herbert; Désiré Collen; B Dahlbäck; Peter Carmeliet
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.
Nature medicine 2001;7(2):215-21.
2001: B Arza; Marc De Maeyer; Jordi Félez; Désiré Collen; H Roger Lijnen
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3).
European journal of biochemistry / FEBS 2001;268(3):826-31.
2001: Peter Sinnaeve; J D Chiche; Z Nong; Olivier Varenne; Natascha Van Pelt; Hilde Gillijns; Désiré Collen; Kenneth D Bloch; Stefan Janssens
Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects.
Circulation research 2001;88(1):103-9.
2001: Désiré Collen
Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2001;():1-9.
2001: Bart De Geest; Sophie Van Linthout; Désiré Collen
Sustained expression of human apo A-I following adenoviral gene transfer in mice.
Gene therapy 2001;8(2):121-7.
2001: Marinee K L Chuah; Désiré Collen; Thierry VandenDriessche
Gene therapy for hemophilia.
The journal of gene medicine 2001;3(1):3-20.
2000: Werner Budts; Peter Pokreisz; Z Nong; Natascha Van Pelt; Hilde Gillijns; Robert D Gerard; R Lyons; Désiré Collen; Kenneth D Bloch; Stefan Janssens
Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
Circulation 2000;102(23):2880-5.
2000: H Roger Lijnen; B Arza; Berthe Van Hoef; Désiré Collen; Paul J Declerck
Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).
The Journal of biological chemistry 2000;275(48):37645-50.
2000: B Arza; Marc F Hoylaerts; Jordi Félez; Désiré Collen; H Roger Lijnen
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator.
European journal of biochemistry / FEBS 2000;267(21):6378-84.
2000: Désiré Collen; Peter Sinnaeve; E Demarsin; H Moreau; Marc De Maeyer; L Jespers; Yves Laroche; Frans Van de Werf
Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction.
Circulation 2000;102(15):1766-72.
2000: Bart De Geest; DOMINIQuE STENGEL; Michele Landeloos; Marleen Lox; L Le Gat; Désiré Collen; Paul Holvoet; Ewa Ninio
Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(10):E68-75.
2000: Gregor Theilmeier; Bart De Geest; P P Van Veldhoven; DOMINIQuE STENGEL; Carine Michiels; Marleen Lox; Michele Landeloos; M J Chapman; Ewa Ninio; Désiré Collen; Bernard Himpens; Paul Holvoet
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(13):2032-9.
2000: Yves Laroche; Stephane Heymans; S Capaert; F De Cock; E Demarsin; Désiré Collen
Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.
Blood 2000;96(4):1425-32.
2000: H Roger Lijnen; Désiré Collen
Molecular basis of thrombolytic therapy.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2000;7(4):373-81.
2000: B Arza; Jordi Félez; P Fábregas; Y Laroche; Désiré Collen; H Roger Lijnen
Plasminogen binding properties of macrophage inflammatory protein (MIP)-2alpha.
Thrombosis and haemostasis 2000;84(1):71-7.
2000: Olivier Varenne; Peter Sinnaeve; Hilde Gillijns; B Iung; Veerle Laurysens; K Meurrens; B Bout; D Valerio; Désiré Collen; Stefan Janssens; Robert D Gerard
Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries.
Human gene therapy 2000;11(9):1329-39.
2000: H Roger Lijnen; Florea Lupu; Désiré Collen; François Le Naour; Claude Boucheix
CD9 gene deficiency does not affect smooth muscle cell migration and neointima formation after vascular injury in mice.
Thrombosis and haemostasis 2000;83(6):956-61.
2000: Esther Creemers; Jack P M Cleutjens; J Smits; Stephane Heymans; Lieve Moons; Désiré Collen; Mat Daemen; Peter Carmeliet
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.
The American journal of pathology 2000;156(6):1865-73.
2000: H Roger Lijnen; Berthe Van Hoef; Mieke Dewerchin; Désiré Collen
Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(6):1488-92.
2000: Myriam Baes; Steven Huyghe; Peter Carmeliet; Peter E Declercq; Désiré Collen; Guy P Mannaerts; Paul P Van Veldhoven
Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids.
The Journal of biological chemistry 2000;275(21):16329-36.
2000: Peter Carmeliet; Désiré Collen
Molecular basis of angiogenesis. Role of VEGF and VE-cadherin.
Annals of the New York Academy of Sciences 2000;902():249-62; discussion 262-4.
2000: Stephane Heymans; S Vanderschueren; Raymond Verhaeghe; Luc Stockx; Hendrik Lacroix; André Nevelsteen; Yves Laroche; Désiré Collen
Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion.
Thrombosis and haemostasis 2000;83(5):666-71.
2000: Paul W Armstrong; Jeffrey R Burton; D Palisaitis; Christopher Thompson; Frans Van de Werf; B Rose; Désiré Collen; Koon K Teo
Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS).
American heart journal 2000;139(5):820-3.
2000: Marinee K L Chuah; An Van Damme; H Zwinnen; I Goovaerts; V Vanslembrouck; Désiré Collen; Thierry VandenDriessche
Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice.
Human gene therapy 2000;11(5):729-38.
2000: Paul Holvoet; Johan Van Cleemput; Désiré Collen; Johan Vanhaecke
Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(3):698-702.
2000: Edward M Conway; Saskia Pollefeyt; J Cornelissen; I DeBaere; Marta Steiner-Mosonyi; K Ong; M Baens; Désiré Collen; Andre C Schuh
Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions.
Blood 2000;95(4):1435-42.
2000: Mieke Dewerchin; Z Liang; Lieve Moons; Peter Carmeliet; Francis J Castellino; Désiré Collen; Elliot D Rosen
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.
Thrombosis and haemostasis 2000;83(2):185-90.
2000: Peter Carmeliet; Désiré Collen
Transgenic mouse models in angiogenesis and cardiovascular disease.
The Journal of pathology 2000;190(3):387-405.
2000: Paul Holvoet; Bart De Geest; Sophie Van Linthout; Marleen Lox; Sophie Danloy; K Raes; Désiré Collen
The Arg123-Tyr166 central domain of human ApoAI is critical for lecithin:cholesterol acyltransferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenic mice.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(2):459-66.
2000: S Vanwetswinkel; Stephane Plaisance; Z Zhi-Yong; I Vanlinthout; Kathleen Brepoels; Ignace Lasters; Désiré Collen; L Jespers
Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase.
Blood 2000;95(3):936-42.
2000: H Roger Lijnen; Berthe Van Hoef; F Ugwu; Désiré Collen; Ivo Roelants
Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium Sp.
Biochemistry 2000;39(2):479-88.
2000: Bart De Geest; Sophie Van Linthout; Marleen Lox; Désiré Collen; Paul Holvoet
Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer.
Human gene therapy 2000;11(1):101-12.
1999: Nobuo Nagai; I Vanlinthout; Désiré Collen
Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Circulation 1999;100(25):2541-6.
1999: H Roger Lijnen; P Soloway; Désiré Collen
Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice.
Circulation research 1999;85(12):1186-91.
1999: Peter Sinnaeve; Olivier Varenne; Désiré Collen; Stefan Janssens
Gene therapy in the cardiovascular system: an update.
Cardiovascular research 1999;44(3):498-506.
1999: H Roger Lijnen; Berthe Van Hoef; I Vanlinthout; M Verstreken; M C Rio; Désiré Collen
Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(12):2863-70.
1999: Pascal Merchiers; F Bulens; Ingrid Stockmans; Astrid De Vriese; R Convents; Roger Bouillon; Désiré Collen; A Belayew; Geert Carmeliet
1,25-Dihydroxyvitamin D(3) induction of the tissue-type plasminogen activator gene is mediated through its multihormone-responsive enhancer.
FEBS letters 1999;460(2):289-96.
1999: Gregor Theilmeier; T Lenaerts; C Remacle; Désiré Collen; Jos Vermylen; Marc F Hoylaerts
Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress.
Blood 1999;94(8):2725-34.
1999: Stephane Heymans; Aernout Luttun; Dieter Nuyens; Gregor Theilmeier; Esther Creemers; Lieve Moons; G D Dyspersin; Jack P M Cleutjens; M Shipley; A Angellilo; M Levi; O Nübe; A Baker; Eli Keshet; Florea Lupu; Jean-Marc Herbert; Jos F M Smits; S D Shapiro; Myriam Baes; M Borgers; Désiré Collen; Mat J A P Daemen; Peter Carmeliet
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Nature medicine 1999;5(10):1135-42.
1999: F Ugwu; Griet Lemmens; Désiré Collen; H Roger Lijnen
Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).
Thrombosis and haemostasis 1999;82(3):1127-31.
1999: Thierry VandenDriessche; V Vanslembrouck; I Goovaerts; H Zwinnen; M L Vanderhaeghen; Désiré Collen; Marinee K L Chuah
Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(18):10379-84.
1999: Jan Gabriels; MC Beckers; H Ding; Astrid De Vriese; Stephane Plaisance; Silvère M van der Maarel; George W Padberg; R R Frants; Jane E Hewitt; Désiré Collen; A Belayew
Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element.
Gene 1999;236(1):25-32.
1999: H Roger Lijnen; Désiré Collen
Matrix metalloproteinase system deficiencies and matrix degradation.
Thrombosis and haemostasis 1999;82(2):837-45.
1999: Désiré Collen
The plasminogen (fibrinolytic) system.
Thrombosis and haemostasis 1999;82(2):259-70.
1999: Pascal Merchiers; F Bulens; Astrid De Vriese; Désiré Collen; A Belayew
Involvement of Sp1 in basal and retinoic acid induced transcription of the human tissue-type plasminogen activator gene.
FEBS letters 1999;456(1):149-54.
1999: Peter Carmeliet; Maria Grazia Lampugnani; Lieve Moons; Ferruccio Breviario; Veerle Compernolle; Françoise Bono; Giovanna Balconi; Raffaella Spagnuolo; B Oosthuyse; Mieke Dewerchin; Adriana Zanetti; A Angellilo; Virginie Mattot; Dieter Nuyens; Esther Lutgens; Frédéric Clotman; M C de Ruiter; A Gittenberger-de Groot; R Poelmann; Florea Lupu; Jean-Marc Herbert; Désiré Collen; Elisabetta Dejana
Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis.
Cell 1999;98(2):147-57.
1999: H Ding; A M Benotmane; G Suske; Désiré Collen; A Belayew
Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human plasminogen activator inhibitor-1 gene.
The Journal of biological chemistry 1999;274(28):19573-80.
1999: L Jespers; H Roger Lijnen; S Vanwetswinkel; Berthe Van Hoef; Kathleen Brepoels; Désiré Collen; Marc De Maeyer
Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface.
Journal of molecular biology 1999;290(2):471-9.
1999: Edward M Conway; Saskia Pollefeyt; J Cornelissen; I DeBaere; Marta Steiner-Mosonyi; Jeffrey I Weitz; H Weiler-Guettler; Peter Carmeliet; Désiré Collen
Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development.
Blood 1999;93(10):3442-50.
1999: Paul Holvoet; Désiré Collen; Frans Van de Werf
Malondialdehyde-modified LDL as a marker of acute coronary syndromes.
JAMA : the journal of the American Medical Association 1999;281(18):1718-21.
1999: Nobuo Nagai; Maria De Mol; H Roger Lijnen; Peter Carmeliet; Désiré Collen
Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
Circulation 1999;99(18):2440-4.
1999: S Rabhi-Sabile; Marta Steiner-Mosonyi; Saskia Pollefeyt; Désiré Collen; Bruno Pouvelle; Jurg Gysin; MC Boffa; Edward M Conway
Plasmodium falciparum-infected erythrocytes: a mutational analysis of cytoadherence via murine thrombomodulin.
Thrombosis and haemostasis 1999;81(5):815-21.
1999: H Roger Lijnen; Florea Lupu; Lieve Moons; Peter Carmeliet; David Goulding; Désiré Collen
Temporal and topographic matrix metalloproteinase expression after vascular injury in mice.
Thrombosis and haemostasis 1999;81(5):799-807.
1999: Olivier Varenne; Robert D Gerard; Peter Sinnaeve; Hilde Gillijns; Désiré Collen; Stefan Janssens
Percutaneous adenoviral gene transfer into porcine coronary arteries: is catheter-based gene delivery adapted to coronary circulation?
Human gene therapy 1999;10(7):1105-15.
1999: Peter Carmeliet; Yin-Shan Ng; Dieter Nuyens; Gregor Theilmeier; Koen Brusselmans; I Cornelissen; E Ehler; V V Kakkar; Ingeborg Stalmans; Virginie Mattot; J C Perriard; Mieke Dewerchin; Willem Flameng; Andras Nagy; Florea Lupu; Lieve Moons; Désiré Collen; Patricia A D'Amore; David T Shima
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.
Nature medicine 1999;5(5):495-502.
1999: L Jespers; S Vanwetswinkel; H Roger Lijnen; N Van Herzeele; Berthe Van Hoef; E Demarsin; Désiré Collen; Marc De Maeyer
Structural and functional basis of plasminogen activation by staphylokinase.
Thrombosis and haemostasis 1999;81(4):479-85.
1999: H Roger Lijnen; K Okada; Osamu Matsuo; Désiré Collen; Mieke Dewerchin
Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding.
Blood 1999;93(7):2274-81.
1999: Michael Praus; K Wauterickx; Désiré Collen; Robert D Gerard
Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors.
Gene therapy 1999;6(2):227-36.
1999: JC Chan; Peter Carmeliet; Lieve Moons; Elliot D Rosen; ZF Huang; George J Broze; Désiré Collen; Francis J Castellino
Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit.
The Journal of clinical investigation 1999;103(4):475-82.
1999: Peter Carmeliet; Désiré Collen
Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development.
Current topics in microbiology and immunology 1999;237():133-58.
1998: Lieve Moons; C Shi; V Ploplis; E Plow; E Haber; Désiré Collen; Peter Carmeliet
Reduced transplant arteriosclerosis in plasminogen-deficient mice.
The Journal of clinical investigation 1998;102(10):1788-97.
1998: LR Jalbert; Elliot D Rosen; Lieve Moons; JC Chan; Peter Carmeliet; Désiré Collen; Francis J Castellino
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.
The Journal of clinical investigation 1998;102(8):1481-8.
1998: Paul Holvoet; Johan Vanhaecke; Stefan Janssens; Frans Van de Werf; Désiré Collen
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.
Circulation 1998;98(15):1487-94.
1998: H Ding; MC Beckers; Stephane Plaisance; Peter Marynen; Désiré Collen; A Belayew
Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous to 3.3 kb dispersed repeated elements.
Human molecular genetics 1998;7(11):1681-94.
1998: Peter Carmeliet; Désiré Collen
Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system.
Thrombosis research 1998;91(6):255-85.
1998: S Jenné; Kathleen Brepoels; Désiré Collen; L Jespers
High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(6):3161-8.
1998: Marinee K L Chuah; Désiré Collen; Thierry VandenDriessche
Gene therapy for hemophilia: hopes and hurdles.
Critical reviews in oncology/hematology 1998;28(3):153-71.
1998: Olivier Varenne; Sorin V Pislaru; Hilde Gillijns; Natascha Van Pelt; Robert D Gerard; P Zoldhelyi; Frans Van de Werf; Désiré Collen; Stefan Janssens
Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs.
Circulation 1998;98(9):919-26.
1998: Khalid Bajou; Agnès Noël; Robert D Gerard; Véronique Masson; Nils Brunner; C Holst-Hansen; Mihaela Skobe; Norbert E Fusenig; Peter Carmeliet; Désiré Collen; Jean-Michel Foidart
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Nature medicine 1998;4(8):923-8.
1998: Peter Carmeliet; Yuval Dor; Jean-Marc Herbert; D Fukumura; Koen Brusselmans; Mieke Dewerchin; Michal Neeman; Françoise Bono; Rinat Abramovitch; P Maxwell; C J Koch; P Ratcliffe; Lieve Moons; R K Jain; Désiré Collen; E Keshert; E Keshet
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
Nature 1998;394(6692):485-90.
1998: Paul Holvoet; Sophie Danloy; Els Deridder; Marleen Lox; Hilde Bernar; A Dhoest; Désiré Collen
Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
The Journal of clinical investigation 1998;102(2):379-85.
1998: Peter Carmeliet; L Moons; Désiré Collen
Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis.
Cardiovascular research 1998;39(1):8-33.
1998: Z Liang; A Cooper; ME DeFord; Peter Carmeliet; Désiré Collen; Francis J Castellino; Elliot D Rosen
Cloning and characterization of a cDNA encoding murine coagulation factor X.
Thrombosis and haemostasis 1998;80(1):87-91.
1998: H Roger Lijnen; Berthe Van Hoef; Florea Lupu; Lieve Moons; Peter Carmeliet; Désiré Collen
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(7):1035-45.
1998: Peter Carmeliet; Désiré Collen
Tissue factor.
The international journal of biochemistry & cell biology 1998;30(6):661-7.
1998: H Roger Lijnen; J Silence; Griet Lemmens; Liesbeth Frederix; Désiré Collen
Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Thrombosis and haemostasis 1998;79(6):1171-6.
1998: Peter Carmeliet; Désiré Collen
Vascular development and disorders: molecular analysis and pathogenic insights.
Kidney international 1998;53(6):1519-49.
1998: F Ugwu; Berthe Van Hoef; A Bini; Désiré Collen; H Roger Lijnen
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).
Biochemistry 1998;37(20):7231-6.
1998: L Jespers; N Van Herzeele; H Roger Lijnen; Berthe Van Hoef; Marc De Maeyer; Désiré Collen; Ignace Lasters
Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex.
Biochemistry 1998;37(18):6380-6.
1998: Stefan Janssens; D Flaherty; Z Nong; Olivier Varenne; Natascha Van Pelt; C Haustermans; P Zoldhelyi; Robert D Gerard; Désiré Collen
Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats.
Circulation 1998;97(13):1274-81.
1998: H Roger Lijnen; F Ugwu; A Bini; Désiré Collen
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3).
Biochemistry 1998;37(14):4699-702.
1998: H Roger Lijnen; J Silence; Berthe Van Hoef; Désiré Collen
Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice.
Blood 1998;91(6):2045-53.
1998: Stephane Heymans; Raymond Verhaeghe; Luc Stockx; Désiré Collen
Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis.
Thrombosis and haemostasis 1998;79(3):517-9.
1998: Paul Holvoet; Gregor Theilmeier; B Shivalkar; Willem Flameng; Désiré Collen
LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(3):415-22.
1998: Désiré Collen
Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent.
Nature medicine 1998;4(3):279-84.
1998: Marinee K L Chuah; Hilde Brems; V Vanslembrouck; Désiré Collen; Thierry VandenDriessche
Bone marrow stromal cells as targets for gene therapy of hemophilia A.
Human gene therapy 1998;9(3):353-65.
1998: LR Jalbert; Elliot D Rosen; A Lissens; Peter Carmeliet; Désiré Collen; Francis J Castellino
Nucleotide structure and characterization of the murine gene encoding anticoagulant protein C.
Thrombosis and haemostasis 1998;79(2):310-6.
1998: Peter Carmeliet; Lieve Moons; Mieke Dewerchin; S Rosenberg; Jean-Marc Herbert; Florea Lupu; Désiré Collen
Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.
The Journal of cell biology 1998;140(1):233-45.
1998: Paul Holvoet; Jean Marie Stassen; Johan Van Cleemput; Désiré Collen; Johan Vanhaecke
Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(1):100-7.
1997: Bart De Geest; Z Zhao; Désiré Collen; Paul Holvoet
Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice.
Circulation 1997;96(12):4349-56.
1997: Peter Carmeliet; Lieve Moons; Roger Lijnen; Myriam Baes; V Lemaître; P Tipping; Angela F Drew; Y Eeckhout; S Shapiro; Florea Lupu; Désiré Collen
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.
Nature genetics 1997;17(4):439-44.
1997: Elliot D Rosen; JC Chan; E Idusogie; Frédéric Clotman; G Vlasuk; T Luther; LR Jalbert; S Albrecht; L Zhong; A Lissens; Luc Schoonjans; Lieve Moons; Désiré Collen; Francis J Castellino; Peter Carmeliet
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding.
Nature 1997;390(6657):290-4.
1997: Peter Carmeliet; Lieve Moons; Roger Lijnen; Stefan Janssens; Florea Lupu; Désiré Collen; Robert D Gerard
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice.
Circulation 1997;96(9):3180-91.
1997: Peter Carmeliet; Désiré Collen
Genetic analysis of blood vessel formation role of endothelial versus smooth muscle cells.
Trends in cardiovascular medicine 1997;7(8):271-81.
1997: Paul Holvoet; Désiré Collen
beta-VLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):2376-82.
1997: Peter Carmeliet; Désiré Collen
Molecular analysis of blood vessel formation and disease.
The American journal of physiology 1997;273(5 Pt 2):H2091-104.
1997: Z Nong; Marc F Hoylaerts; Natascha Van Pelt; Désiré Collen; Stefan Janssens
Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats.
Circulation research 1997;81(5):865-9.
1997: Peter Carmeliet; Lieve Moons; Jean-Marc Herbert; James Crawley; Florea Lupu; Roger Lijnen; Désiré Collen
Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice.
Circulation research 1997;81(5):829-39.
1997: P Holvoet; Désiré Collen
Thrombosis and atherosclerosis.
Current opinion in lipidology 1997;8(5):320-8.
1997: Robert D Gerard; Désiré Collen
Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis.
Cardiovascular research 1997;35(3):451-8.
1997: K Okada; H Roger Lijnen; Mieke Dewerchin; A Belayew; Osamu Matsuo; Désiré Collen; R Bernaerts
Characterization and targeting of the murine alpha2-antiplasmin gene.
Thrombosis and haemostasis 1997;78(3):1104-10.
1997: S Vanderschueren; I Van Vlaenderen; Désiré Collen
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model.
Stroke; a journal of cerebral circulation 1997;28(9):1783-8.
1997: Myriam Baes; Pierre Gressens; Eveline Baumgart; Peter Carmeliet; Minne Casteels; Marc Fransen; Philippe Evrard; Dariush Fahimi; Peter E Declercq; Désiré Collen; Paul P Van Veldhoven; Guy P Mannaerts
A mouse model for Zellweger syndrome.
Nature genetics 1997;17(1):49-57.
1997: Peter Carmeliet; Jean Marie Stassen; I Van Vlaenderen; R S Meidell; Désiré Collen; Robert D Gerard
Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice.
Blood 1997;90(4):1527-34.
1997: F Rolling; Z Nong; S Pisvin; Désiré Collen
Adeno-associated virus-mediated gene transfer into rat carotid arteries.
Gene therapy 1997;4(8):757-61.
1997: S Vanderschueren; Joseph Dens; P Kerdsinchai; Walter Desmet; Mathias Vrolix; F De Man; P Van den Heuvel; L Hermans; Désiré Collen; Frans Van de Werf
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.
American heart journal 1997;134(2 Pt 1):213-9.
1997: A M Benotmane; M F Hoylaerts; Désiré Collen; A Belayew
Nonisotopic quantitative analysis of protein-DNA interactions at equilibrium.
Analytical biochemistry 1997;250(2):181-5.
1997: Désiré Collen
Thrombolytic therapy.
Thrombosis and haemostasis 1997;78(1):742-6.
1997: L Jespers; S Jenné; Ignace Lasters; Désiré Collen
Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage.
Journal of molecular biology 1997;269(5):704-18.
1997: A Dhoest; Z Zhao; Bart De Geest; Els Deridder; Alain Sillen; Yves Engelborghs; Désiré Collen; Paul Holvoet
Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation.
The Journal of biological chemistry 1997;272(25):15967-72.
1997: H Roger Lijnen; Ignace Lasters; M Verstreken; Désiré Collen; L Jespers
Screening panels of monoclonal antibodies using phage-displayed antigen.
Analytical biochemistry 1997;248(2):211-5.
1997: Paul Holvoet; Sophie Danloy; Désiré Collen
Role of the carboxy-terminal domain of human apolipoprotein AI in high-density-lipoprotein metabolism--a study based on deletion and substitution variants in transgenic mice.
European journal of biochemistry / FEBS 1997;245(3):642-7.
1997: Peter Carmeliet; Lieve Moons; Mieke Dewerchin; Nigel Mackman; T Luther; Georg Breier; V Ploplis; M Müller; Andras Nagy; E Plow; Robert D Gerard; T Edgington; Werner Risau; Désiré Collen
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Annals of the New York Academy of Sciences 1997;811():191-206.
1997: P Carmeliet; Désiré Collen
Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis.
Current opinion in lipidology 1997;8(2):118-25.
1997: Ignace Lasters; N Van Herzeele; H Roger Lijnen; Désiré Collen; L Jespers
Enzymatic properties of phage-displayed fragments of human plasminogen.
European journal of biochemistry / FEBS 1997;244(3):946-52.
1997: H Roger Lijnen; E F Wagner; Désiré Collen
Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Thrombosis and haemostasis 1997;77(2):362-7.
1997: Peter Carmeliet; Lieve Moons; Jean Marie Stassen; Maria De Mol; Ann Bouché; Joost J van den Oord; Mark Kockx; Désiré Collen
Vascular wound healing and neointima formation induced by perivascular electric injury in mice.
The American journal of pathology 1997;150(2):761-76.
1997: Désiré Collen; Luc Stockx; Hendrik Lacroix; R Suy; S Vanderschueren
Recombinant staphylokinase variants with altered immunoreactivity. IV: Identification of variants with reduced antibody induction but intact potency.
Circulation 1997;95(2):463-72.
1997: Désiré Collen; F De Cock; E Demarsin; S Jenné; Ignace Lasters; Yves Laroche; PA Warmerdam; L Jespers
Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns.
Circulation 1997;95(2):455-62.
1997: Peter Carmeliet; Lieve Moons; V Ploplis; E Plow; Désiré Collen
Impaired arterial neointima formation in mice with disruption of the plasminogen gene.
The Journal of clinical investigation 1997;99(2):200-8.
1997: Edward M Conway; Saskia Pollefeyt; Désiré Collen; Marta Steiner-Mosonyi
The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis.
Blood 1997;89(2):652-61.
1997: F Bulens; Pascal Merchiers; I Ibañez-Tallon; Astrid De Vriese; Luc Nelles; Frank Claessens; A Belayew; Désiré Collen
Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene.
The Journal of biological chemistry 1997;272(1):663-71.
1996: E Idusogie; Elliot D Rosen; Peter Carmeliet; Désiré Collen; Francis J Castellino
Nucleotide structure and characterization of the murine blood coagulation factor VII gene.
Thrombosis and haemostasis 1996;76(6):957-64.
1996: K Okada; H Roger Lijnen; H Moreau; S Vanderschueren; Désiré Collen
Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Thrombosis and haemostasis 1996;76(6):857-9.
1996: L Schoonjans; G M Albright; J L Li; Désiré Collen; R W Moreadith
Pluripotential rabbit embryonic stem (ES) cells are capable of forming overt coat color chimeras following injection into blastocysts.
Molecular reproduction and development 1996;45(4):439-43.
1996: A Gase; Manfred Hartmann; Karl-Heinz Gührs; A Röcker; Désiré Collen; D Behnke; Bernhard Schlott
Functional significance of NH2- and COOH-terminal regions of staphylokinase in plasminogen activation.
Thrombosis and haemostasis 1996;76(5):755-60.
1996: Paul Holvoet; J Donck; M Landeloos; E Brouwers; K Luijtens; Jef Arnout; E Lesaffre; Yves Vanrenterghem; Désiré Collen
Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.
Thrombosis and haemostasis 1996;76(5):663-9.
1996: H Roger Lijnen; Berthe Van Hoef; Désiré Collen
Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.
European journal of biochemistry / FEBS 1996;241(3):840-8.
1996: Z Nong; Jean Marie Stassen; Lieve Moons; Désiré Collen; Stefan Janssens
Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.
Circulation 1996;94(8):1941-7.
1996: Désiré Collen; S Vanderschueren; Frans Van de Werf
Fibrin-selective thrombolytic therapy with recombinant staphylokinase.
Haemostasis 1996;26 Suppl 4():294-300.
1996: Peter Carmeliet; Désiré Collen
Genetic analysis of the plasminogen and coagulation system in mice.
Haemostasis 1996;26 Suppl 4():132-53.
1996: S Vanderschueren; Désiré Collen; Frans Van de Werf
A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.
Thrombosis and haemostasis 1996;76(4):541-4.
1996: Peter Carmeliet; Nigel Mackman; Lieve Moons; Thomas Luther; P Gressens; I Van Vlaenderen; H Demunck; M Kasper; G Breier; P Evrard; M Müller; W Risau; T Edgington; Désiré Collen
Role of tissue factor in embryonic blood vessel development.
Nature 1996;383(6595):73-5.
1996: Paul Holvoet; Z Zhao; Els Deridder; A Dhoest; Désiré Collen
Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.
The Journal of biological chemistry 1996;271(32):19395-401.
1996: Y Y Huang; M E Bach; Hans-Peter Lipp; Min Zhuo; David P Wolfer; Robert D Hawkins; L Schoonjans; Eric R Kandel; J M Godfraind; R Mulligan; Désiré Collen; Peter Carmeliet
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(16):8699-704.
1996: H Roger Lijnen; Peter Carmeliet; A Bouché; Lieve Moons; VA Ploplis; Edward F Plow; Désiré Collen
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen.
Blood 1996;88(3):870-6.
1996: Stefan Janssens; Kenneth D Bloch; Z Nong; Robert D Gerard; P Zoldhelyi; Désiré Collen
Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats.
The Journal of clinical investigation 1996;98(2):317-24.
1996: Désiré Collen; H Moreau; Luc Stockx; S Vanderschueren
Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction.
Circulation 1996;94(2):207-16.
1996: Désiré Collen; R Bernaerts; Paul J Declerck; F De Cock; E Demarsin; S Jenné; Y Laroche; H Roger Lijnen; K Silence; M Verstreken
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.
Circulation 1996;94(2):197-206.
1996: S Vanderschueren; Jean Marie Stassen; Désiré Collen
Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model.
Journal of cardiovascular pharmacology 1996;27(6):809-15.
1996: H Ding; K Descheemaeker; Peter Marynen; Luc Nelles; T Carvalho; M Carmo-Fonseca; Désiré Collen; A Belayew
Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene.
DNA and cell biology 1996;15(6):429-42.
1996: S Vanderschueren; Désiré Collen
Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
Thrombosis and haemostasis 1996;75(5):816-9.
1996: Peter Carmeliet; Valerie Ferreira; G Breier; Saskia Pollefeyt; L Kieckens; Marina Gertsenstein; M Fahrig; A Vandenhoeck; K Harpal; C Eberhardt; C Declercq; J Pawling; Lieve Moons; Désiré Collen; W Risau; Andras Nagy
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.
Nature 1996;380(6573):435-9.
1996: E Idusogie; E Rosen; J P Geng; Peter Carmeliet; Désiré Collen; Francis J Castellino
Characterization of a cDNA encoding murine coagulation factor VII.
Thrombosis and haemostasis 1996;75(3):481-7.
1996: Désiré Collen
Fibrin-selective thrombolytic therapy for acute myocardial infarction.
Circulation 1996;93(5):857-65.
1996: Mieke Dewerchin; A V Nuffelen; G Wallays; A Bouché; Lieve Moons; Peter Carmeliet; R C Mulligan; Désiré Collen
Generation and characterization of urokinase receptor-deficient mice.
The Journal of clinical investigation 1996;97(3):870-8.
1996: Peter Carmeliet; Désiré Collen
Gene manipulation and transfer of the plasminogen and coagulation system in mice.
Seminars in thrombosis and hemostasis 1996;22(6):525-42.
1995: H Roger Lijnen; S Wnendt; J Schneider; E Janocha; Berthe Van Hoef; Désiré Collen; G J Steffens
Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
European journal of biochemistry / FEBS 1995;234(1):350-7.
1995: K Silence; Manfred Hartmann; Karl-Heinz Gührs; A Gase; Bernhard Schlott; Désiré Collen; H Roger Lijnen
Structure-function relationships in staphylokinase as revealed by "clustered charge to alanine" mutagenesis.
The Journal of biological chemistry 1995;270(45):27192-8.
1995: Paul J Declerck; M Verstreken; Désiré Collen
Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Thrombosis and haemostasis 1995;74(5):1305-9.
1995: VA Ploplis; Peter Carmeliet; S Vazirzadeh; I Van Vlaenderen; Lieve Moons; Edward F Plow; Désiré Collen
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.
Circulation 1995;92(9):2585-93.
1995: S Vanderschueren; Luc Stockx; Guido Wilms; H Lacroix; Raymond Verhaeghe; Jos Vermylen; Désiré Collen
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase.
Circulation 1995;92(8):2050-7.
1995: S Vanderschueren; L Barrios; P Kerdsinchai; P Van den Heuvel; L Hermans; Mathias Vrolix; Frits H A F de Man; Edouard Benit; L Muyldermans; Désiré Collen
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
Circulation 1995;92(8):2044-9.
1995: H Roger Lijnen; Lieve Moons; V Beelen; P Carmelie; Désiré Collen
Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Thrombosis and haemostasis 1995;74(4):1126-31.
1995: Peter Carmeliet; Désiré Collen
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Trends in cardiovascular medicine 1995;5(4):117-22.
1995: Peter Carmeliet; Désiré Collen
Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system.
Thrombosis and haemostasis 1995;74(1):429-36.
1995: H Roger Lijnen; Désiré Collen
Fibrinolytic agents: mechanisms of activity and pharmacology.
Thrombosis and haemostasis 1995;74(1):387-90.
1995: Désiré Collen; H Roger Lijnen
Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Thrombosis and haemostasis 1995;74(1):167-71.
1995: M Verstraete; H Roger Lijnen; Désiré Collen
Thrombolytic agents in development.
Drugs 1995;50(1):29-42.
1995: Paul Holvoet; G Perez; Z Zhao; E Brouwers; H Bernar; Désiré Collen
Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
The Journal of clinical investigation 1995;95(6):2611-9.
1995: Désiré Collen; H Roger Lijnen
New thrombolytic agents and strategies.
Baillière's clinical haematology 1995;8(2):425-35.
1995: H Roger Lijnen; Désiré Collen
Mechanisms of physiological fibrinolysis.
Baillière's clinical haematology 1995;8(2):277-90.
1995: H Roger Lijnen; Jean Marie Stassen; Désiré Collen
Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Thrombosis and haemostasis 1995;73(5):845-9.
1995: Paul J Declerck; P Carmeliet; M Verstreken; F De Cock; Désiré Collen
Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice.
The Journal of biological chemistry 1995;270(15):8397-400.
1995: P Rodríguez; P Fuentes; M Barro; J G Alvarez; E Muñoz; Désiré Collen; H Roger Lijnen
Structural domains of streptokinase involved in the interaction with plasminogen.
European journal of biochemistry / FEBS 1995;229(1):83-90.
1995: F Bulens; I Ibañez-Tallon; P Van Acker; Astrid De Vriese; Luc Nelles; A Belayew; Désiré Collen
Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobases.
The Journal of biological chemistry 1995;270(13):7167-75.
1995: L Jun; Jef Arnout; P Vanhove; Frédérique Dol; JC Lormeau; J M Herbert; Désiré Collen; Frans Van de Werf
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Coronary artery disease 1995;6(3):257-63.
1995: H Roger Lijnen; Berthe Van Hoef; Désiré Collen
Interactions of staphylokinase with human platelets.
Thrombosis and haemostasis 1995;73(3):472-7.
1995: Peter Carmeliet; A Bouché; C De Clercq; S Janssen; Saskia Pollefeyt; S Wyns; R C Mulligan; Désiré Collen
Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice.
Annals of the New York Academy of Sciences 1995;748():367-81; discussion 381-2.
1995: Désiré Collen; H Roger Lijnen; S Vanderschueren
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Verhandelingen - Koninklijke Academie voor Geneeskunde van België 1995;57(3):183-96; discussion 196-8.
1994: Peter Carmeliet; R C Mulligan; Désiré Collen
Transgenic animals as tools for the study of fibrinolysis in vivo.
Journal of internal medicine 1994;236(4):455-9.
1994: Désiré Collen; D P De Bono; H Roger Lijnen; H Pannekoek
Development of novel thrombolytic agents.
Journal of internal medicine 1994;236(4):433-7.
1994: H Roger Lijnen; Fedor Bachmann; Désiré Collen; V Ellis; H Pannekoek; D C Rijken; S Thorsen
Mechanisms of plasminogen activation.
Journal of internal medicine 1994;236(4):415-24.
1994: H Roger Lijnen; Berthe Van Hoef; V Beelen; Désiré Collen
Characterization of the murine plasma fibrinolytic system.
European journal of biochemistry / FEBS 1994;224(3):863-71.
1994: H Roger Lijnen; F De Cock; Désiré Collen
Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
European journal of biochemistry / FEBS 1994;224(2):567-74.
1994: H Roger Lijnen; F De Cock; Berthe Van Hoef; Bernhard Schlott; Désiré Collen
Characterization of the interaction between plasminogen and staphylokinase.
European journal of biochemistry / FEBS 1994;224(1):143-9.
1994: S Vanderschueren; Jean Marie Stassen; Désiré Collen
On the immunogenicity of recombinant staphylokinase in patients and in animal models.
Thrombosis and haemostasis 1994;72(2):297-301.
1994: Désiré Collen; H Roger Lijnen
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
Blood 1994;84(3):680-6.
1994: A M Audenaert; I Knockaert; Désiré Collen; Paul J Declerck
Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
The Journal of biological chemistry 1994;269(30):19559-64.
1994: Désiré Collen; Jean Marie Stassen; T Yasuda; Canio Refino; N Paoni; B Keyt; Tania Roskams; J L Guerrero; H Roger Lijnen; Herman K Gold
Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Thrombosis and haemostasis 1994;72(1):98-104.
1994: Désiré Collen
Is there an optimal thrombolytic regimen?
Coronary artery disease 1994;5(4):287-91.
1994: Peter Carmeliet; L Schoonjans; L Kieckens; B Ream; J Degen; R Bronson; R De Vos; Joost J van den Oord; Désiré Collen; R C Mulligan
Physiological consequences of loss of plasminogen activator gene function in mice.
Nature 1994;368(6470):419-24.
1994: R G Kiss; Jean Marie Stassen; Hans Deckmyn; Tania Roskams; Herman K Gold; Edward F Plow; Désiré Collen
Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(3):375-80.
1994: R G Kiss; H R Lu; Tania Roskams; I K Jang; Edward F Plow; Herman K Gold; Désiré Collen
Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(3):367-74.
1994: Bernhard Schlott; Manfred Hartmann; Karl-Heinz Gührs; E Birch-Hirschfeld; A Gase; S Vettermann; Désiré Collen; H Roger Lijnen
Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
Biochimica et biophysica acta 1994;1204(2):235-42.
1994: H D Garabedian; Herman K Gold; J B Newell; Désiré Collen; J N Hagstrom; E G Bovill
Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris.
Blood 1994;83(4):1155.
1994: Bernhard Schlott; Manfred Hartmann; Karl-Heinz Gührs; E Birch-Hirschfeid; H D Pohl; S Vanderschueren; F Van de Werf; A Michoel; Désiré Collen; D Behnke
High yield production and purification of recombinant staphylokinase for thrombolytic therapy.
Bio/technology (Nature Publishing Company) 1994;12(2):185-9.
1994: Paul Holvoet; G Perez; H Bernar; E Brouwers; Berlinda Vanloo; M Rosseneu; Désiré Collen
Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation.
The Journal of clinical investigation 1994;93(1):89-98.
1994: Désiré Collen; H R Lu; Jean Marie Stassen; Ingrid Vreys; T Yasuda; S Bunting; Herman K Gold
Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.
Thrombosis and haemostasis 1994;71(1):95-102.
1994: S Ueshima; Paul Holvoet; H Roger Lijnen; Luc Nelles; V Seghers; Désiré Collen
Expression and characterization of clustered charge-to-alanine mutants of low M(r) single-chain urokinase-type plasminogen activator.
Thrombosis and haemostasis 1994;71(1):134-40.
1994: Paul J Declerck; S Vanderschueren; J Billiet; H Moreau; Désiré Collen
Prevalence and induction of circulating antibodies against recombinant staphylokinase.
Thrombosis and haemostasis 1994;71(1):129-33.
1993: Désiré Collen; H R Lijnen
On the future of thrombolytic therapy for acute myocardial infarction.
The American journal of cardiology 1993;72(19):46G-50G.
1993: Peter Carmeliet; Jean Marie Stassen; L Schoonjans; B Ream; Joost J van den Oord; Maria De Mol; R C Mulligan; Désiré Collen
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.
The Journal of clinical investigation 1993;92(6):2756-60.
1993: Peter Carmeliet; L Kieckens; L Schoonjans; B Ream; A van Nuffelen; G Prendergast; M Cole; R Bronson; Désiré Collen; R C Mulligan
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.
The Journal of clinical investigation 1993;92(6):2746-55.
1993: C Kohmura; Herman K Gold; T Yasuda; R Holt; M A Nedelman; J Luis Guerrero; H F Weisman; Désiré Collen
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1993;13(12):1837-42.
1993: Frans Van de Werf; H Roger Lijnen; Désiré Collen
Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
Coronary artery disease 1993;4(10):929-33.
1993: S Ueshima; K Silence; Désiré Collen; H Roger Lijnen
Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma.
Thrombosis and haemostasis 1993;70(3):495-9.
1993: H Roger Lijnen; V Beelen; Paul J Declerck; Désiré Collen
Bio-immunoassay for staphylokinase in blood.
Thrombosis and haemostasis 1993;70(3):491-4.
1993: Désiré Collen; Berthe Van Hoef; Bernhard Schlott; Manfred Hartmann; Karl-Heinz Gührs; H Roger Lijnen
Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
European journal of biochemistry / FEBS 1993;216(1):307-14.
1993: K Silence; Désiré Collen; H Roger Lijnen
Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.
Blood 1993;82(4):1175-83.
1993: H Roger Lijnen; Berthe Van Hoef; R A Smith; Désiré Collen
Functional properties of p-anisoylated plasmin-staphylokinase complex.
Thrombosis and haemostasis 1993;70(2):326-31.
1993: Frans Van de Werf; L Janssens; T Brzostek; Luc Mortelmans; F J Wackers; G M Willems; Hein Heidbüchel; E Lesaffre; I Scheys; Désiré Collen
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.
Journal of the American College of Cardiology 1993;22(2):407-16.
1993: Désiré Collen
Towards improved thrombolytic therapy.
Lancet 1993;342(8862):34-6.
1993: Désiré Collen; Frans Van de Werf
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.
Circulation 1993;87(6):1850-3.
1993: K Silence; Désiré Collen; H Roger Lijnen
Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin.
The Journal of biological chemistry 1993;268(13):9811-6.
1993: Jean Marie Stassen; H J Rapold; I Vanlinthout; Désiré Collen
Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.
Thrombosis and haemostasis 1993;69(5):454-9.
1993: T Yasuda; Herman K Gold; C Kohmura; L Guerrero; H Yaoita; J T Fallon; Stuart Bunting; Désiré Collen
Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1993;13(5):738-47.
1993: Désiré Collen; Bernhard Schlott; Yves Engelborghs; Berthe Van Hoef; Manfred Hartmann; H Roger Lijnen; D Behnke
On the mechanism of the activation of human plasminogen by recombinant staphylokinase.
The Journal of biological chemistry 1993;268(11):8284-9.
1993: Désiré Collen; F De Cock; Jean Marie Stassen
Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Circulation 1993;87(3):996-1006.
1993: Paul Holvoet; Mieke Dewerchin; Jean Marie Stassen; H Roger Lijnen; T Tollenaere; P J Gaffney; Désiré Collen
Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Circulation 1993;87(3):1007-16.
1993: Paul Holvoet; Y Laroche; Jean Marie Stassen; H Roger Lijnen; Berthe Van Hoef; F De Cock; A Van Houtven; Y Gansemans; G Matthyssens; Désiré Collen
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
Blood 1993;81(3):696-703.
1993: H Roger Lijnen; Berthe Van Hoef; Désiré Collen
Interaction of staphylokinase with different molecular forms of plasminogen.
European journal of biochemistry / FEBS 1993;211(1-2):91-7.
1993: H Roger Lijnen; Désiré Collen
Molecular interactions between tissue-type plasminogen activator and plasminogen.
Methods in enzymology 1993;223():197-206.
1992: Paul Holvoet; Y Laroche; H Roger Lijnen; Berthe Van Hoef; E Brouwers; F De Cock; M Lauwereys; Y Gansemans; Désiré Collen
Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
European journal of biochemistry / FEBS 1992;210(3):945-52.
1992: H Roger Lijnen; Désiré Collen
Remaining perspectives of mutant and chimeric plasminogen activators.
Annals of the New York Academy of Sciences 1992;667():357-64.
1992: Désiré Collen; H Roger Lijnen
Fibrin-specific fibrinolysis.
Annals of the New York Academy of Sciences 1992;667():259-71.
1992: Y Imura; Jean Marie Stassen; Ingrid Vreys; E Lesaffre; Herman K Gold; Désiré Collen
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Thrombosis and haemostasis 1992;68(3):336-40.
1992: X K Li; H Roger Lijnen; Luc Nelles; M H Hu; Désiré Collen
Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Biochimica et biophysica acta 1992;1159(1):37-43.
1992: Y Imura; Jean Marie Stassen; S Bunting; F Stockmans; Désiré Collen
Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
Blood 1992;80(5):1247-53.
1992: Jef Arnout; M Simoons; D de Bono; H J Rapold; Désiré Collen; M Verstraete
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Journal of the American College of Cardiology 1992;20(3):513-9.
1992: Mieke Dewerchin; Anne-Mieke Vandamme; Paul Holvoet; F De Cock; Griet Lemmens; H Roger Lijnen; Jean Marie Stassen; Désiré Collen
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Thrombosis and haemostasis 1992;68(2):170-9.
1992: I K Jang; Herman K Gold; R C Leinbach; J T Fallon; Désiré Collen; Josiah N Wilcox
Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1992;12(8):948-54.
1992: K A Descheemaeker; S Wyns; Luc Nelles; Johan Auwerx; T Ny; Désiré Collen
Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.
The Journal of biological chemistry 1992;267(21):15086-91.
1992: D E Vaughan; Paul J Declerck; E Van Houtte; Maria De Mol; Désiré Collen
Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
Thrombosis and haemostasis 1992;68(1):60-3.
1992: Paul J Declerck; Maria De Mol; D E Vaughan; Désiré Collen
Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
The Journal of biological chemistry 1992;267(17):11693-6.
1992: Y Imura; Jean Marie Stassen; Désiré Collen
Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
The Journal of pharmacology and experimental therapeutics 1992;261(3):895-8.
1992: H R Lu; Herman K Gold; Z Wu; T Yasuda; Patrick Pauwels; H J Rapold; M Napier; S Bunting; Désiré Collen
G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
Thrombosis and haemostasis 1992;67(6):686-91.
1992: H J Rapold; T Stassen; Frans Van de Werf; Désiré Collen
Comparative copper coil-induced thrombogenicity of the internal mammary, left anterior descending coronary, and popliteal arteries in dogs.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1992;12(5):639-44.
1992: Y Imura; Jean Marie Stassen; T Kurokawa; S Iwasa; H Roger Lijnen; Désiré Collen
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
Blood 1992;79(9):2322-9.
1992: H R Lu; Z Wu; Patrick Pauwels; H Roger Lijnen; Désiré Collen
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Journal of the American College of Cardiology 1992;19(6):1350-9.
1992: H Roger Lijnen; X K Li; Luc Nelles; M H Hu; Désiré Collen
Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
European journal of biochemistry / FEBS 1992;205(2):701-9.
1992: Luc Nelles; X K Li; I Vanlinthout; F De Cock; H Roger Lijnen; Désiré Collen
Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
Thrombosis and haemostasis 1992;67(4):445-52.
1992: F Bulens; Luc Nelles; N Van den Panhuyzen; Désiré Collen
Stimulation by retinoids of tissue-type plasminogen activator secretion in cultured human endothelial cells: relations of structure to effect.
Journal of cardiovascular pharmacology 1992;19(4):508-14.
1992: Anne-Mieke Vandamme; Mieke Dewerchin; H Roger Lijnen; H Bernar; F Bulens; Luc Nelles; Désiré Collen
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
European journal of biochemistry / FEBS 1992;205(1):139-46.
1992: H J Rapold; D de Bono; A E Arnold; Jef Arnout; F De Cock; Désiré Collen; M Verstraete
Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
Circulation 1992;85(3):928-34.
1992: H Roger Lijnen; P D Webb; Berthe Van Hoef; F De Cock; Jean Marie Stassen; S D Prior; Désiré Collen
Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
Thrombosis and haemostasis 1992;67(2):239-47.
1992: Désiré Collen; Luc Nelles; F De Cock; Griet Lemmens; T Van Coetsem; E Demarsin; H Roger Lijnen
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Thrombosis research 1992;65(3):421-38.
1992: Paul J Declerck; L Van Keer; M Verstreken; Désiré Collen
An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
Thrombosis and haemostasis 1992;67(1):95-100.
1992: X K Li; H Roger Lijnen; Luc Nelles; Berthe Van Hoef; Jean Marie Stassen; Désiré Collen
Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Blood 1992;79(2):417-29.
1992: H Roger Lijnen; Berthe Van Hoef; Osamu Matsuo; Désiré Collen
On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin.
Biochimica et biophysica acta 1992;1118(2):144-8.
1992: Désiré Collen
Designing thrombolytic agents: focus on safety and efficacy.
The American journal of cardiology 1992;69(2):71A-81A.
1992: H Jacobs; Frans Van de Werf; E Lesaffre; H De Geest; Désiré Collen
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.
Acta clinica Belgica 1992;47(2):82-9.
1991: Désiré Collen; H Roger Lijnen
Basic and clinical aspects of fibrinolysis and thrombolysis.
Blood 1991;78(12):3114-24.
1991: T Kurokawa; S Iwasa; A Kakinuma; Jean Marie Stassen; H Roger Lijnen; Désiré Collen
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Thrombosis and haemostasis 1991;66(6):684-93.
1991: E A Thompson; Luc Nelles; Désiré Collen
Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells.
European journal of biochemistry / FEBS 1991;201(3):627-32.
1991: Paul Holvoet; Y Laroche; H Roger Lijnen; R Van Cauwenberge; E Demarsin; E Brouwers; G Matthyssens; Désiré Collen
Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
The Journal of biological chemistry 1991;266(29):19717-24.
1991: H Roger Lijnen; Jean Marie Stassen; I Vanlinthout; H Fukao; K Okada; Osamu Matsuo; Désiré Collen
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Thrombosis and haemostasis 1991;66(4):468-73.
1991: Y Laroche; M Demaeyer; Jean Marie Stassen; Y Gansemans; E Demarsin; G Matthyssens; Désiré Collen; Paul Holvoet
Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer.
The Journal of biological chemistry 1991;266(25):16343-9.
1991: Désiré Collen; H R Lu; H Roger Lijnen; Luc Nelles; Jean Marie Stassen
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Circulation 1991;84(3):1216-34.
1991: Mieke Dewerchin; Désiré Collen
Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies.
Bioconjugate chemistry 1991;2(5):293-300.
1991: Mieke Dewerchin; H Roger Lijnen; Jean Marie Stassen; F De Cock; T Quertermous; M H Ginsberg; Edward F Plow; Désiré Collen
Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Blood 1991;78(4):1005-18.
1991: D E Vaughan; E Van Houtte; Paul J Declerck; Désiré Collen
Streptokinase-induced platelet aggregation. Prevalence and mechanism.
Circulation 1991;84(1):84-91.
1991: H R Lu; H Roger Lijnen; Jean Marie Stassen; Désiré Collen
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Blood 1991;78(1):125-31.
1991: H Roger Lijnen; Berthe Van Hoef; F De Cock; K Okada; S Ueshima; Osamu Matsuo; Désiré Collen
On the mechanism of fibrin-specific plasminogen activation by staphylokinase.
The Journal of biological chemistry 1991;266(18):11826-32.
1991: Jean Marie Stassen; H Roger Lijnen; L Kieckens; Désiré Collen
Small animal thrombosis models for the evaluation of thrombolytic agents.
Circulation 1991;83(6 Suppl):IV65-72.
1991: Herman K Gold; T Yasuda; I K Jang; J Luis Guerrero; J T Fallon; R C Leinbach; Désiré Collen
Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Circulation 1991;83(6 Suppl):IV26-40.
1991: Paul J Declerck; H Roger Lijnen; M Verstreken; Désiré Collen
Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
Thrombosis and haemostasis 1991;65(4):394-8.
1991: H D Garabedian; Herman K Gold; R C Leinbach; T A Svizzero; D M Finkelstein; J Luis Guerrero; Désiré Collen
Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin.
Journal of the American College of Cardiology 1991;17(5):1213-22.
1991: H Roger Lijnen; Berthe Van Hoef; Désiré Collen
On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
The Journal of biological chemistry 1991;266(7):4041-4.
1991: H Roger Lijnen; Désiré Collen
Towards the development of improved thrombolytic agents.
British journal of haematology 1991;77(3):261-6.
1991: T Yasuda; Herman K Gold; R C Leinbach; H Yaoita; J T Fallon; L Guerrero; M A Napier; Stuart Bunting; Désiré Collen
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Circulation 1991;83(3):1038-47.
1991: H J Rapold; H R Lu; Z M Wu; H Nijs; Désiré Collen
Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.
Blood 1991;77(5):1020-4.
1991: Désiré Collen; H Roger Lijnen; I Vanlinthout; L Kieckens; Luc Nelles; Jean Marie Stassen
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
Thrombosis and haemostasis 1991;65(2):174-80.
1991: K Bartha; Paul J Declerck; H Moreau; Luc Nelles; Désiré Collen
Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator.
The Journal of biological chemistry 1991;266(2):792-7.
1991: H Roger Lijnen; Désiré Collen
New strategies in the development of thrombolytic agents.
Current studies in hematology and blood transfusion 1991;(58):69-72.
1991: Désiré Collen; H Roger Lijnen
Thrombolytic therapy.
Annals of the New York Academy of Sciences 1991;614():259-69.
1991: F Bulens; Anne-Mieke Vandamme; H Bernar; Luc Nelles; Roger Lijnen; Désiré Collen
Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer.
European journal of biochemistry / FEBS 1991;195(1):235-42.
1990: T Yasuda; Herman K Gold; R C Leinbach; T Saito; J Luis Guerrero; I K Jang; R Holt; J T Fallon; Désiré Collen
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Journal of the American College of Cardiology 1990;16(7):1728-35.
1990: I K Jang; Herman K Gold; R C Leinbach; J T Fallon; Désiré Collen
In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Circulation research 1990;67(6):1552-61.
1990: M Sabovic; H Roger Lijnen; D Keber; Désiré Collen
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.
Thrombosis and haemostasis 1990;64(3):450-4.
1990: D E Vaughan; Paul J Declerck; E Van Houtte; Maria De Mol; Désiré Collen
Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo.
Circulation research 1990;67(5):1281-6.
1990: Désiré Collen; Mieke Dewerchin; H J Rapold; H Roger Lijnen; Jean Marie Stassen
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Circulation 1990;82(5):1744-53.
1990: H J Rapold; Z M Wu; T Stassen; Frans Van de Werf; Désiré Collen
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Blood 1990;76(8):1558-63.
1990: Anne-Mieke Vandamme; F Bulens; H Bernar; Luc Nelles; Roger Lijnen; Désiré Collen
Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment-D dimer.
European journal of biochemistry / FEBS 1990;192(3):767-75.
1990: T Yasuda; Herman K Gold; H Yaoita; R C Leinbach; J Luis Guerrero; I K Jang; R Holt; J T Fallon; Désiré Collen
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Journal of the American College of Cardiology 1990;16(3):714-22.
1990: H Roger Lijnen; Berthe Van Hoef; F De Cock; Désiré Collen
Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
Thrombosis and haemostasis 1990;64(1):61-8.
1990: Luc Nelles; H Roger Lijnen; A Van Nuffelen; E Demarsin; Désiré Collen
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Thrombosis and haemostasis 1990;64(1):53-60.
1990: Herman K Gold; Lawrence W Gimple; T Yasuda; R C Leinbach; W Werner; R Holt; R Jordan; H Berger; Désiré Collen; Barry S Coller
Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
The Journal of clinical investigation 1990;86(2):651-9.
1990: Z Wu; Frans Van de Werf; T Stassen; C Mattsson; G Pohl; Désiré Collen
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model.
Journal of cardiovascular pharmacology 1990;16(2):197-203.
1990: Désiré Collen; H Roger Lijnen; F Bulens; Anne-Mieke Vandamme; A Tulinsky; Luc Nelles
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
The Journal of biological chemistry 1990;265(21):12184-91.
1990: Désiré Collen; H Roger Lijnen
Molecular mechanisms of thrombolysis: implications for therapy.
Biochemical pharmacology 1990;40(2):177-86.
1990: Paul J Declerck; H Roger Lijnen; M Verstreken; H Moreau; Désiré Collen
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Blood 1990;75(9):1794-800.
1990: H Roger Lijnen; Luc Nelles; Berthe Van Hoef; F De Cock; Désiré Collen
Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
The Journal of biological chemistry 1990;265(10):5677-83.
1990: Désiré Collen
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
Annals of internal medicine 1990;112(7):529-38.
1990: H Roger Lijnen; Berthe Van Hoef; Luc Nelles; Désiré Collen
Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
The Journal of biological chemistry 1990;265(9):5232-6.
1990: H Roger Lijnen; Mieke Dewerchin; F De Cock; Désiré Collen
Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Thrombosis research 1990;57(3):333-42.
1990: Paul J Declerck; Désiré Collen
Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays.
Thrombosis research. Supplement 1990;10():3-9.
1990: I K Jang; Herman K Gold; A A Ziskind; R C Leinbach; J T Fallon; Désiré Collen
Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Circulation 1990;81(1):219-25.
1990: Désiré Collen; Herman K Gold
New developments in thrombolytic therapy.
Thrombosis research. Supplement 1990;10():105-31.
1990: Désiré Collen; Herman K Gold
New developments in thrombolytic therapy.
Advances in experimental medicine and biology 1990;281():333-54.
1990: H Roger Lijnen; Berthe Van Hoef; Désiré Collen
On the molecular interactions between fibrin, tissue-type plasminogen activator and plasminogen.
Thrombosis research. Supplement 1990;10():45-54.
1989: M Sabovic; H Roger Lijnen; D Keber; Désiré Collen
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Thrombosis and haemostasis 1989;62(4):1083-7.
1989: Mieke Dewerchin; H Roger Lijnen; Berthe Van Hoef; F De Cock; Désiré Collen
Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
European journal of biochemistry / FEBS 1989;185(1):141-9.
1989: D E Vaughan; M E Mendelsohn; Paul J Declerck; E Van Houtte; Désiré Collen; J Loscalzo
Characterization of the binding of human tissue-type plasminogen activator to platelets.
The Journal of biological chemistry 1989;264(27):15869-74.
1989: A E Arnold; R W Brower; Désiré Collen; Gerrit-Anne van Es; J Lubsen; Patrick Washington Serruys; Maarten L Simoons; M Verstraete
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Journal of the American College of Cardiology 1989;14(3):581-8.
1989: Lawrence W Gimple; Herman K Gold; R C Leinbach; Barry S Coller; W Werner; T Yasuda; J A Johns; A A Ziskind; D Finkelstein; Désiré Collen
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Circulation 1989;80(3):581-8.
1989: V Ballegeer; Bernard Spitz; L Kieckens; H Moreau; A Van Assche; Désiré Collen
Predictive value of increased plasma levels of fibronectin in gestational hypertension.
American journal of obstetrics and gynecology 1989;161(2):432-6.
1989: D E Vaughan; Paul J Declerck; Maria De Mol; Désiré Collen
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.
The Journal of clinical investigation 1989;84(2):586-91.
1989: H Roger Lijnen; Berthe Van Hoef; F De Cock; Désiré Collen
The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
Blood 1989;73(7):1864-72.
1989: T Yasuda; Herman K Gold; J T Fallon; R C Leinbach; H D Garabedian; J Luis Guerrero; Désiré Collen
A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
Journal of the American College of Cardiology 1989;13(6):1409-14.
1989: Paul Holvoet; Jean Marie Stassen; Y Hashimoto; D Spriggs; P Devos; Désiré Collen
Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits.
Thrombosis and haemostasis 1989;61(2):307-13.
1989: Y Hashimoto; Jean Marie Stassen; B Leclef; M De Roo; A Vandecruys; J Melin; D Verhoeven-Mester; A Trouet; Désiré Collen
Thrombus imaging with an I-123-labeled F(ab')2 fragment of an anti-human fibrin monoclonal antibody in a rabbit model.
Radiology 1989;171(1):223-6.
1989: D J Spriggs; Jean Marie Stassen; Y Hashimoto; Désiré Collen
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Blood 1989;73(5):1207-12.
1989: I K Jang; Herman K Gold; A A Ziskind; J T Fallon; R E Holt; R C Leinbach; J W May; Désiré Collen
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
Circulation 1989;79(4):920-8.
1989: D Spriggs; Herman K Gold; Y Hashimoto; E Van Houtte; Jos Vermylen; Désiré Collen
Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
Thrombosis and haemostasis 1989;61(1):93-6.
1989: A A Ziskind; Herman K Gold; T Yasuda; M Kanke; J Luis Guerrero; J T Fallon; T Saito; Désiré Collen
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Circulation 1989;79(2):393-9.
1989: H Roger Lijnen; Désiré Collen
Interaction of heparin with histidine-rich glycoprotein.
Annals of the New York Academy of Sciences 1989;556():181-5.
1988: H Roger Lijnen; Luc Nelles; Berthe Van Hoef; E Demarsin; Désiré Collen
Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
The Journal of biological chemistry 1988;263(35):19083-91.
1988: H Roger Lijnen; Luc Nelles; Berthe Van Hoef; E Demarsin; Désiré Collen
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
European journal of biochemistry / FEBS 1988;177(3):575-82.
1988: H Roger Lijnen; Luc Nelles; Berthe Van Hoef; F De Cock; Désiré Collen
Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Thrombosis and haemostasis 1988;60(2):247-50.
1988: Paul J Declerck; Maria De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; Désiré Collen
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
The Journal of biological chemistry 1988;263(30):15454-61.
1988: H Roger Lijnen; Désiré Collen
New strategies in the development of thrombolytic agents.
Blut 1988;57(4):147-62.
1988: J A Johns; Herman K Gold; R C Leinbach; T Yasuda; Lawrence W Gimple; W Werner; D Finkelstein; J Newell; A A Ziskind; Désiré Collen
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Circulation 1988;78(3):546-56.
1988: M C Alessi; Paul J Declerck; Maria De Mol; Luc Nelles; Désiré Collen
Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).
European journal of biochemistry / FEBS 1988;175(3):531-40.
1988: Désiré Collen
Fibrin-specific thrombolytic agents.
Archives des maladies du coeur et des vaisseaux 1988;81 Spec No():19-23.
1988: H Roger Lijnen; Luc Nelles; W E Holmes; Désiré Collen
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
The Journal of biological chemistry 1988;263(12):5594-8.
1988: Désiré Collen; I Juhan-Vague
Fibrinolysis and atherosclerosis.
Seminars in thrombosis and hemostasis 1988;14(2):180-3.
1988: H D Garabedian; Herman K Gold; R C Leinbach; T Yasuda; J A Johns; D Thornton; Désiré Collen
Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.
Thrombosis research 1988;50(1):121-33.
1988: H D Garabedian; Herman K Gold; T Yasuda; J A Johns; D M Finkelstein; R J Gaivin; C Cobbaert; R C Leinbach; Désiré Collen
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiography.
Journal of the American College of Cardiology 1988;11(4):729-34.
1988: Désiré Collen
Synergism of thrombolytic agents: investigational procedures and clinical potential.
Circulation 1988;77(4):731-5.
1988: T Yasuda; Herman K Gold; J T Fallon; R C Leinbach; J Luis Guerrero; L E Scudder; M Kanke; D Shealy; M J Ross; Désiré Collen
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
The Journal of clinical investigation 1988;81(4):1284-91.
1988: P Cambier; Frans Van de Werf; G R Larsen; Désiré Collen
Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
Journal of cardiovascular pharmacology 1988;11(4):468-72.
1988: Herman K Gold; Barry S Coller; T Yasuda; T Saito; J T Fallon; J Luis Guerrero; R C Leinbach; A A Ziskind; Désiré Collen
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
Circulation 1988;77(3):670-7.
1988: H Roger Lijnen; Berthe Van Hoef; Luc Nelles; W E Holmes; Désiré Collen
Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1988;172(1):185-8.
1988: Paul J Declerck; M C Alessi; M Verstreken; Egbert Kruithof; I Juhan-Vague; Désiré Collen
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.
Blood 1988;71(1):220-5.
1988: H Roger Lijnen; Désiré Collen
Mechanisms of plasminogen activation by mammalian plasminogen activators.
Enzyme 1988;40(2-3):90-6.
1988: Désiré Collen; D C Stump; Herman K Gold
Thrombolytic therapy.
Annual review of medicine 1988;39():405-23.
1988: Désiré Collen
Potential approaches for therapeutic intervention of thrombosis by fibrinolytic agents.
Seminars in thrombosis and hemostasis 1988;14(1):95-9.
1988: M Verstraete; M Bory; Désiré Collen; R Erbel; R J Lennane; D Mathey; H R Michels; M Schartl; R Uebis; R Bernard
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Klinische Wochenschrift 1988;66 Suppl 12():77-85.
1988: Désiré Collen
Fibrin-specific thrombolytic agents.
Klinische Wochenschrift 1988;66 Suppl 12():15-23.
1988: Désiré Collen; Jean Marie Stassen; G Larsen
Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.
Blood 1988;71(1):216-9.
1988: Désiré Collen
Fibrin-specific thrombolytic therapy.
Thrombosis research. Supplement 1988;8():3-14.
1988: Désiré Collen
Fibrin-specific thrombolytic agents.
Annales de biologie clinique 1988;46(3):195-200.
1988: Johan Auwerx; Roger Bouillon; Désiré Collen; J Geboers
Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Arteriosclerosis (Dallas, Tex.) 1988;8(1):68-72.
1987: V Ballegeer; P Mombaerts; Paul J Declerck; Bernard Spitz; F André Van Assche; Désiré Collen
Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy.
Thrombosis and haemostasis 1987;58(4):1030-2.
1987: Paul J Declerck; P Mombaerts; Paul Holvoet; Maria De Mol; Désiré Collen
Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
Thrombosis and haemostasis 1987;58(4):1024-9.
1987: H Roger Lijnen; Berthe Van Hoef; Désiré Collen
Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
European journal of biochemistry / FEBS 1987;169(2):359-64.
1987: Désiré Collen
Fibrin-specific thrombolytic agents.
Schweizerische medizinische Wochenschrift 1987;117(46):1791-8.
1987: Herman K Gold; J A Johns; R C Leinbach; T Yasuda; Désiré Collen
Thrombolytic therapy for unstable angina pectoris: rationale and results.
Journal of the American College of Cardiology 1987;10(5 Suppl B):91B-95B.
1987: Désiré Collen
Molecular mechanism of action of newer thrombolytic agents.
Journal of the American College of Cardiology 1987;10(5 Suppl B):11B-15B.
1987: Désiré Collen; Jean Marie Stassen; F De Cock
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Thrombosis and haemostasis 1987;58(3):943-6.
1987: Jean Marie Stassen; I Juhan-Vague; M C Alessi; F De Cock; Désiré Collen
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
Thrombosis and haemostasis 1987;58(3):947-50.
1987: W E Holmes; H Roger Lijnen; Luc Nelles; C Kluft; H K Nieuwenhuis; D C Rijken; Désiré Collen
Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity.
Science (New York, N.Y.) 1987;238(4824):209-11.
1987: W E Holmes; H Roger Lijnen; Désiré Collen
Characterization of recombinant human alpha 2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site.
Biochemistry 1987;26(16):5133-40.
1987: Luc Nelles; H Roger Lijnen; Désiré Collen; W E Holmes
Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
The Journal of biological chemistry 1987;262(22):10855-62.
1987: H Roger Lijnen; W E Holmes; Berthe Van Hoef; B Wiman; H Rodriguez; Désiré Collen
Amino-acid sequence of human alpha 2-antiplasmin.
European journal of biochemistry / FEBS 1987;166(3):565-74.
1987: M Verstraete; A E Arnold; R W Brower; Désiré Collen; D P de Bono; C De Zwaan; R Erbel; W S Hillis; R J Lennane; J Lubsen
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
The American journal of cardiology 1987;60(4):231-7.
1987: Herman K Gold; J A Johns; R C Leinbach; T Yasuda; E Grossbard; R Zusman; Désiré Collen
A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
Circulation 1987;75(6):1192-9.
1987: Luc Nelles; H Roger Lijnen; Désiré Collen; W E Holmes
Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
The Journal of biological chemistry 1987;262(12):5682-9.
1987: H D Garabedian; Herman K Gold; R C Leinbach; J A Johns; T Yasuda; M Kanke; Désiré Collen
Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Journal of the American College of Cardiology 1987;9(3):599-607.
1987: W E Holmes; Luc Nelles; H Roger Lijnen; Désiré Collen
Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin).
The Journal of biological chemistry 1987;262(4):1659-64.
1987: D C Stump; Jean Marie Stassen; E Demarsin; Désiré Collen
Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
Blood 1987;69(2):592-6.
1986: H D Garabedian; Herman K Gold; R C Leinbach; T Yasuda; J A Johns; Désiré Collen
Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.
The American journal of cardiology 1986;58(9):673-9.
1986: Désiré Collen; F De Cock; E Demarsin; H Roger Lijnen; D C Stump
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Thrombosis and haemostasis 1986;56(1):35-9.
1986: Herman K Gold; R C Leinbach; H D Garabedian; T Yasuda; J A Johns; E B Grossbard; I Palacios; Désiré Collen
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.
Circulation 1986;73(2):347-52.
1985: M Verstraete; W Bleifeld; R W Brower; B Charbonnier; Désiré Collen; D P de Bono; A J Dunning; R J Lennane; J Lubsen; D G Mathey
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction.
Lancet 1985;2(8462):965-9.
1985: M Verstraete; R Bernard; M Bory; R W Brower; Désiré Collen; D P de Bono; R Erbel; W Huhmann; R J Lennane; J Lubsen
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
Lancet 1985;1(8433):842-7.

FIND

DISCOVER

PROMOTE

Désiré Collen

Research Profile

Chemicals & Drugs

Living Beings

Physiology

Anatomy

Procedures

Concepts & Ideas

Disorders

Genes & Molecular Sequences